2011 FNIH Annual Report

Fifteen and Forward* 2011 Annual Report

*Celebrating 15 years, 1996–2011

“When I came on board in 1997, it was just the executive director, Anne

Alexander, and me. In the beginning, we were known as the National

Foundation for Biomedical Research. We had nine donors and started with

$200,000. The NIH gave us office space on its campus in Building 60—the

Cloister—and we had our first board meeting in the chapel.

Some of the early programs included the Clinical Research Training Program

(CRTP), made possible by funding from Pfizer Inc; The Biomedical Engineering

Summer Internship Program, made possible by a grant

from the Whitaker Foundation and the Neuroimmunology

Fellowship supported by the Penates Foundation. Mrs.

Lenore Salzman set up a memorial fund very early on as a

tribute to her late husband, Dr. Norman P. Salzman, to

support an award and symposium in Virology.

I’ve met so many wonderful people—originally I got to see

every one of the CRTP Fellows once a month when they

picked their checks up from me. I was chatting once with one

of the CRTP Fellows, Dr. Eric Eskiolgu, and I told him that one of my heroes was

pediatric neurosurgeon Dr. Benjamin Carson and that I had read some of his

books and gone to one of his lectures. He said, ‘Oh, I’m meeting with him today.’

He came back with a business card signed by him, which I treasure to this day.

Where we started and what we’ve become is just amazing. We helped build

the Edmond J. Safra Family Lodge with funding from Mrs. Lily Safra and the

Edmond J. Safra Philanthropic Foundation. To see the lodge go from what

was just a parking lot to this incredible building was mind-boggling. We’ve

had so many, many, many accomplishments—the mHealth Summit, the Bill

& Melinda Gates Foundation grants—really it’s just the tip of the iceberg.

To say the least, we have come a long way from our humble beginning,

and I have such appreciation and pride for the Foundation. I know we

are making a difference in this world.”

PEGGY J. GERLACHER Operations Associate and longest-serving FNIH staff member

Fifteen and Forward: Progress Through PartnershipsEstablished by Congress to assist the National Institutes of Health (NIH) in its

mission of improving human health, the Foundation for the NIH (FNIH) has steadily

built upon its modest fundraising beginnings

in 1996 to become a diverse and dynamic

organization, both highly efficient and effective

in its work. We have evolved into a unique and

innovative designer and manager of the

creative and complex partnerships that

today’s health challenges demand.

Guided by the priorities and goals of the

NIH, our job is to identify and tackle urgent

biomedical problems whose solutions are

beyond the reach of any single entity or organization.

Operating outside the confines of a federal agency,

we can surmount the barriers between the public

and private sectors to bring together the best ideas,

resources and funds.

As a neutral convener among partners, we serve an important function in preventing conflicts of

interest on the one hand, and preserving proprietary integrity on the other. This allows us to combine

the talents and efforts of nontraditional collaborators—and even competitors—around a common goal.

In addition to the NIH, our partners include other federal agencies, universities, institutes, corporations,

foundations, associations and individuals.

The role of the FNIH varies according to the nature and needs of the particular partnership from

discrete tasks such as raising funds and organizing meetings, to grant making, scientific oversight

and overall program leadership. We work with nearly all 27 institutes and centers of the NIH, on

programs large and small, from projects focused on training and education, to clinical trials seeking

discoveries in mental health, cancer and many other diseases, to multi-site global initiatives affecting

millions of people and embracing scores of partners.

While each is unique, our partnerships all are built around impact, feasibility and inclusiveness.

All stakeholders are integral partners in our programs, from beginning to end. Our Board of Directors

is populated with eminent scientists, scholars, business people and philanthropists who ensure

that each project meets stringent standards and benchmarks for success. By bringing world-class

resources to bear, the Foundation for the NIH and its partners are accelerating the pace of biomedical

research and advancing human health around the globe.

“By facilitating world class collaborations

between the public and private sectors,

the FNIH is able to bring together the

most innovative minds in science.

Through these diverse partnerships,

the FNIH is able to address some of

the most critical health issues

facing patients and their families.”

ELLEN SIGAL, Ph.D.Board Member, Foundation for the National Institutes of Health; Chair, Friends of Cancer Research

F o u n d a t i o n F o r t h e n a t i o n a l i n s t i t u t e s o F h e a l t h W W W. F n i h . o r G | 1

Letter From the Chairman

| 2 0 1 1 A N N U A L R E P O R T2

and Forward

Charles A. Sanders, M.D.Chairman

As the boundaries between traditional

disciplines of science continue to fall away—

and indeed, new disciplines

emerge—the biomedical

discovery horizon stretches in

seemingly limitless directions.

Computational biology,

bioengineering, nanoscience,

proteogenomics and a host of

other convergent fields present

immediate, promising and

unprecedented avenues toward

understanding and advancing

human health. The Foundation for

the NIH—specifically created to foster broad

research collaboration through public-private

partnerships—is at the nexus of this revolution.

In our 15-year lifetime, we have supported

and enabled some of the most important

recent initiatives of the National Institutes

of Health—including the Human Genome

Project, the Genetic Association Information

Network (GAIN), and the Alzheimer’s Disease

Neuroimaging Initiative (ADNI). Scientists

we support collaborate on six continents—in

state-of-the-art laboratories, in poverty-wracked

communities and in dense tropical rainforests to

address health challenges both localized

and global.

Since our founding in 1996, we have raised

more than $600 million in support of over 400

projects. Through the years, we have evolved to

not only raise money for ongoing NIH activities

such as research, training, lectures and patient

support, but to develop programs that leverage

NIH expertise in innovative ways, partnering

with insurers and health plan providers, for

example, to examine medical records to

recognize undocumented drug reactions

(Observational Medical Outcomes Partnership,

OMOP). At the same time, we support basic

science, making available important tools,

such as expansive tissue and data libraries, to

investigators around the world (ADNI, CTC-

VIMC, OMOP).

We engage some of the most prominent

entities in their fields—not only our stalwart

partners in the pharmaceutical industry and

nonprofit organizations such as the Bill &

Melinda Gates Foundation, but corporate

leaders such as Intel, Verizon and Coca-Cola,

which bring novel resources such as wireless

technology and public awareness components

to public health initiatives.

In an era of tight federal funding, we continue

to find new, creative ways to deliver critical

support to NIH institutes and programs—from

in-kind drug donations to the NIH Clinical

Center and room–naming opportunities at the

Edmond J. Safra Family Lodge to video-link

training classes and online tutorials. Even as

we strive to respond to the needs of the NIH,

we maintain a detailed and rigorous protocol

for evaluating the suitability, feasibility and

progress of all potential programs. In this way,

we ensure that our efforts and resources—and,

most importantly, those of our partners—are

employed to do the greatest good.

As we mark our 15-year milestone and move

forward, we are well positioned to support the

NIH and biomedicine across the full spectrum

of existing and yet-to-be-identified challenges,

and thereby contribute to the betterment of

human health.


From fundamental science that peers deep into the recesses of cells to

clinical trials that confirm the safety and efficacy of new patient therapies,

the FNIH creates partnerships that address the world’s most pressing

biomedical challenges. Forming collaborations uniquely suited to the task at

hand, the Foundation can find ways to support research into basic biochemical

processes as well as diseases of global epidemic proportion. Embracing an

ever wider universe of partners, the FNIH is helping the NIH to inform not

only medical science, but regulatory and policy-making agencies that directly

impact health care delivery.

Research

| 2 0 1 1 A N N U A L R E P O R T4

Biomarkers are physiologic traits that enable

researchers to identify and track both normal

and abnormal processes within the body.

Developing these markers is critical to advancing

our understanding of practically all major illnesses

and diseases—from bacterial infections to

Alzheimer’s disease to cancer. Biomarkers

also can play a significant role in determining

the effectiveness and safety of new drugs,

thereby hastening the development of new—

and better targeted—treatments.

Collaborative science is essential to the

development and qualification of biomarkers.

The FNIH-managed Biomarkers Consortium

brings together the resources and expertise

of the NIH, the U.S. Food and Drug Administration

(FDA), and Pharmaceutical Research and

Manufacturers of America (PhRMA) as founding

partners, as well as many other participants

from industry, academia, nonprofit organizations

and other government institutions.

In 2011, the Biomarkers Consortium:

• completed its Alzheimer’s Disease Plasma

Proteomics Project. This project utilized

blood samples from the groundbreaking

Alzheimer’s Disease Neuroimaging Initiative

to qualify biomarkers useful in diagnosing

and monitoring patients;

• submitted interim recommendations to

the FDA for measuring clinical outcomes

of treatments for two common types of

infection, community-acquired bacterial

pneumonia (CABP) and acute bacterial skin

and skin structure infections (ABSSSI). It also

approved the launch of the second phase

of this project, which will seek to develop

new tools to measure these outcomes for

use in clinical trials;

• initiated qualification with the FDA of FDG-

PET and Volumetric CT imaging as markers for

disease progression and response to therapy

in non-Hodgkin’s lymphoma and non-small cell

lung cancer. This effort is making use of data

from two, five-year clinical studies managed

by the National Cancer Institute and funded

through the Consortium;

• launched the Beta Cell Mass and Function

Project, which is an effort to standardize

methods that measure pancreatic beta

cell function and open the door to the

development of new treatments for diabetes.

The ability to track the performance of these

insulin-producing cells should allow for better

detection and monitoring of the progression

of diabetes; and

• launched the Kidney Safety Biomarkers

Project, a major collaboration with the Critical

Path Institute to qualify new urinary biomarkers

of acute drug-induced kidney injury, enabling

more efficient development of safer drugs for a

broad range of diseases.

(continued on page 6)

Five years since its formation, the Biomarkers Consortium

has had a major impact on advancing biomarkers as tools

for improving medicine, having launched 14 projects worth

over $45 million. Consortium projects focus on clinical application and regulatory

qualification of biomarkers, which allows their practical application in streamlining

the development of new treatments and providing more effective patient care.

The Biomarkers Consortium


In addition to the CABP and ABSSSI project,

the Consortium approved two other initiatives

for launch in 2012. The Osteoarthritis

Biomarkers Project will utilize the extensive

resources of another public-private

partnership, the Osteoarthritis Initiative, to

find better ways to predict, measure and

treat this leading cause of disability in older

adults. The Atherosclerosis In Silico Modeling

Project will evaluate the significance of

many different biomarkers involved in the

progression and treatment of atherosclerosis

using advanced computer modeling

techniques. Cardiovascular disease, including

atherosclerosis, is the leading cause of

death in the United States. This work should

support the design of better treatments.

The Biomarkers Consortium (continued from page 5)

“The FNIH Biomarkers Consortium has

set the stage for real progress in the

biomarker ‘pipeline’ by bringing together

teams of highly qualified people to both

identify critical barriers stopping or

slowing development and creating

the necessary projects to address

them. The Biomarkers Consortium

has led a new generation of

pre-competitive partnerships that

leverage the FNIH’s position as a trusted

third party, and is producing important

processes, tools and databases that

are available to all of the relevant

communities. Altogether a great story!”

ANNA D. BARKER, Ph.D. Former Deputy Director of the National Cancer Institute, Current Professor and Director of Arizona State University’s Transformative Healthcare Networks; and Co-Director, Complex Adaptive Systems Initiative

Abbott Laboratories

Academy of Molecular Imaging

Advanced Medical Technology Association

Alzheimer’s Association

American Association for Cancer Research

American Diabetes Association

American Orthopaedic Society for Sports Medicine

American Society of Clinical Oncology

Amgen

Amylin Pharmaceuticals

Arthritis Foundation

Association of Clinical Research Organizations

AstraZeneca

Autism Speaks

Avon Foundation

Banyan Biomarkers

Battelle Memorial Institute

BG Medicine

Biotechnology Industry Organization

Boehringer-Ingelheim

Bristol-Myers Squibb

Celgene Corporation

CHDI Foundation

Daiichi-Sankyo, Inc.

Dairy Research Institute

Eisai, Inc.

Eli Lilly and Company

Federation of Clinical Immunology Societies

GlaxoSmithKline

Hoffman-LaRoche/The Roche Group

International Society of Biological Therapy of Cancer

Johnson & Johnson

Juvenile Diabetes Research Foundation

Kidney Cancer Association

The Leukemia and Lymphoma Society

Merck and Co., Inc.

Metanomics Health GmbH

Michael J. Fox Foundation for Parkinson’s Research

Ontario Cancer Biomarker Network

Orasi Medical, Inc.

Osteoarthritis Research Society International

Pfizer Inc

Pharmaceutical Research and Manufacturers of America

PROOF Centre of Excellence

Radiological Society of North America

RareCyte, Inc.

Rules-Based Medicine

Sunovion Pharmaceuticals

Takeda Pharmaceuticals

United States Pharmacopeial Convention

University of Illinois

XOMA, Ltd.

The Biomarkers Consortium Members

| 2 0 1 1 A N N U A L R E P O R T6

and Forward

As the research community has come to

recognize that the most efficient way to

overcome the difficult problem of creating

an AIDS vaccine is through collaboration and

the sharing of information, tools and materials,

the FNIH has played a key role in facilitating

partnerships among leading HIV/AIDS

researchers through several collaborative projects.

The FNIH was first approached in 2005 by

Dr. Richard Koup, Chief of the Immunology Lab

at the Vaccine Research Center (VRC) at the

National Institute of Allergy and Infectious

Diseases, for assistance in managing a proposal

to the Bill & Melinda Gates Foundation’s newly

established Collaboration for AIDS Vaccine

Discovery (CAVD). The CAVD was founded

to bring the “big science” approach used to

sequence the human genome to bear on

the scourge of HIV/AIDS. Koup’s proposal

was to establish the Comprehensive T Cell

Vaccine Immune Monitoring Consortium (CTC-

VIMC), a collaboration among leading HIV

T cell immunologists who would work to

standardize cellular immunological methods for

monitoring HIV vaccine trials in humans and

non-human primates.

Awarded in the spring of 2006, this was the

largest of the 26 CAVD awards: $33 million to

support the work of 19 international investigators

in 14 institutions. The FNIH assumed

responsibility for the Administrative Core:

• developing sub-award agreements with

consortium collaborators;

• participating in the development of CAVD

guidelines to protect intellectual property

while promoting the availability of health

innovations to those most in need; and

• monitoring fiscal expenditures across

the consortium.

A dedicated project manager was added to the

FNIH team, to play a vital role in advancing the

project’s research agenda, working closely with

Dr. Koup to facilitate communication among

investigators, evaluate progress toward pre-

established project milestones and document

the consortium’s scientific achievements. This

relationship exemplifies the FNIH’s ability to

support the broad collaborative activities of NIH

intramural laboratories.

Completing its first five years in June 2011,

the CTC-VIMC has achieved its objectives as

a central service facility supporting the entire

CAVD. The consortium:

• harmonized and standardized key assays

for evaluating T cell responses across four

clinical core laboratories and the three

non-human primate core laboratories and

published these landmark achievements;

• developed new molecular technologies to

evaluate immune responses, and applied

these methods to the RV144 “Thai” trial,

which provided the first indication that a

vaccine for AIDS could be effective;

• established a new blood cell repository,

a non-human primate cell and tissue

repository, and a reagent core, all of which

support research and assay standardization

efforts across the entire CAVD network; and

• is providing an array of immunological

assays to CAVD-supported Phase 1 clinical

trials and non-human primate vaccine

development initiatives.

Earlier in 2011, the FNIH was invited to submit

a proposal to continue the work of CTC-VIMC.

This was favorably reviewed, and a new award

of $16.8 million has been granted to maintain

this key component of the CAVD infrastructure

through 2016.

Comprehensive T Cell Vaccine Immune Monitoring Consortium

“Partnering with the FNIH has enabled

the VRC to lead the CTC-VIMC—a major

international consortium where

shared ideas are aligned with clinical

development priorities and rigorous

standards are established for AIDS

vaccine testing.”

RICHARD KOUP, M.D. CTC-VIMC Principal Investigator; Chief of the Immunology Laboratory at the Vaccine Research Center at the National Institutes of Health


The Centralized Envelope Comparative

Immunogenicity Phase 1 Trial (CECI) is another

Collaboration for AIDS Vaccine Discovery (CAVD)

program administered by the FNIH. The project

focuses on clinical testing of a novel vaccine

developed through the use of

computational biology to overcome

the vaccine-development

challenges arising from the genetic

diversity of the HIV virus.

Approved in November 2009, this

$6 million project brings together

a new mix of investigators and

institutions, including many major

stakeholders of the Global HIV/

AIDS Vaccine Initiative: the CAVD,

the National Institute of Allergy and Infectious

Diseases (NIAID), the NIAID-supported Center for

HIV/AIDS Vaccine Immunology (CHAVI), the HIV

Vaccine Testing Network (HVTN), as well as the

Vaccine Research Center, EuroVacc and

Sanofi-Pasteur.

This proof-of-concept clinical trial will determine

the relative efficacy of the innovative, computer-

generated “mosaic” vaccine insert against the

naturally occurring wild type virus and a third

“consensus” HIV vaccine insert that represents

the most frequently circulating HIV strains. The

study could pave the way for faster regulatory

clearance of future trials designed using

computational biology and substantially reduce

the timeline for testing new HIV vaccines.

CECI demonstrates how the FNIH can facilitate

external collaboration with an extramural branch

of the NIH, in this case NIAID’s Division of

Acquired Immunodeficiency Syndrome.

Manufacture of the test HIV vaccines is

well underway, with plans to begin the

clinical trial in 2013.

Study by leading researchers, including several

at the Vaccine Research Center (VRC) of “non-

progressors”—those rare individuals infected

with HIV who do not become sick—has pointed

to the role of broadly neutralizing antibodies in

halting disease progression to full-blown AIDS.

The Development of a Second Generation

Broadly Neutralizing Antibody Product to

Prevent HIV-1 Infection is a five-year, $1.8 million

effort to harness one such antibody to better

understand this phenomenon and produce

new tools for the fight against AIDS. Its aim is

Centralized Envelope Comparative Immunogenicity Phase 1 Trial

Development of a Second Generation Broadly Neutralizing Antibody Product to Prevent HIV-1 Infection

The FNIH broadens its portfolio to include biomedical research programs, launching fundraising and partnership development for the Osteoarthritis Initiative, a $60 million public-private partnership involving the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute on Aging (NIA) and other agencies together with four industry partners. The FNIH raises $20.8 million from the private sector for this project.

The National Foundation For Biomedical Research (NFBR) is formed. Established by the United States Congress to support the mission of the National Institutes of Health—improving health through scientific discovery—the Foundation identifies and develops opportunities to leverage NIH resources.

The FNIH begins fundraising for construction of what will become the Edmond J. Safra Family Lodge.

The NFBR launches its first major program—the Clinical Research Training Program (CRTP). To date, the CRTP has enabled 340 of the country’s most promising medical and dental students to experience clinical research firsthand in an intensive, year-long residential training program at the NIH.

The FNIH supports the Mouse Sequencing Genome Project.

Congress approves name change from the National Foundation For Biomedical Research to the Foundation for the National Institutes of Health.

The Norman P. Salzman Memorial Award and Lecture in Virology are established; the events are supported by the newly established Norman P. Salzman Memorial Fund.

1997

2000

1998

1999

1996

FIFTEEN AND FORwARD | A Timeline of Highlights

| 2 0 1 1 A N N U A L R E P O R T8

and Forward

The Observational Medical Outcomes Partnership

(OMOP) was conceived in 2007 and established in

late 2008 as a public-private research partnership

between the FDA, PhRMA and the FNIH.

Entering its fourth year of operations, the effort

continues to build upon its existing research base

by advancing methodological research, sustaining

and improving the accessibility and framework

of the OMOP Research Lab, and enhancing and

expanding OMOP’s tools and capabilities.

OMOP’s mission is to inform the implementation

of a systematic medical product surveillance

system with empirical evidence of the appropriate

methods, data and infrastructure necessary to

identify and track potential relevant safety issues.

OMOP is one of the most ambitious initiatives in

the field, whose research agenda is addressing

data, methods, infrastructure and governance

questions in an open, scientific collaboration.

For the past three years, OMOP has established

and engaged a diverse research community,

guided by a robust governance model with

broad stakeholder representation across two

advisory boards and an executive board. OMOP

now serves as a unique resource to foster

methodological research that includes a secure

high-performance research computing laboratory

and network of data partners with access to de-

identified observational data representing nearly

200 million patients.

The impact of OMOP goes beyond specific

study findings, however. “We’ve created a

very unique resource, an open-source research

environment,” says OMOP Executive Director

Thomas Scarnecchia. “We’ve built a dynamic

community of methodologists, forged new

partnerships with others that go beyond drug

safety-related research.”

OMOP’s framework for organizing, characterizing

and analyzing disparate data sources across a

network of health care and insurance providers

is now being extended and adopted by four

academic and nonprofit health care research

networks within the U.S. and Europe. This growing

adoption of OMOP’s framework, coupled with

the partnership’s open and transparent research

culture, enables OMOP to foster a diverse

community of researchers working together to

advance the science of observational studies

and integrate the new knowledge into improved

standards and practices.

to enhance the potency, efficacy and eventual

clinical utility of the VRC01 monoclonal antibody

through genetic modification.

Launched in November 2011 under the

Collaboration for AIDS Vaccine Discovery

program, this new project is an FNIH

partnership with the Bill & Melinda Gates

Foundation and the NIH. With scientific

leadership at the National Institute of Allergy

and Infectious Diseases’ VRC, collaborators

include Brigham and Women’s Hospital and the

University of Minnesota.

Observational Medical Outcomes Partnership

“Celebrating 50 Years of Neuroscience Research” event commemorating the 50th anniversaries of NINDS and NIMH.

2001

The Helix and the Genome: 50 Years from Model to Medicine celebration includes gala dinner, symposia, exhibits, outreach activities and more.

2003

The Grand Challenges in Global Health (GCGH) initiative is established with a $200 million grant from the Bill & Melinda Gates Foundation. The GCGH encourages innovation to solve persistent health problems in the developing world. See page 10.

The FNIH begins fundraising for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), ultimately raising $27 million for this program. See page 16.

2004

Edmond J. Safra Family Lodge welcomes its first guest.20

05

The FNIH announces the GCGH grantees.

The Imaging Database Resources Initiative (IDRI) launches to improve lung cancer diagnosis and treatment by encouraging development of advanced medical imaging software tools.

Dean R. O’Neill Renal Cell Cancer Research Fund and Dr. Edward T. Rancic Memorial Fund are established to raise funds for kidney cancer research. See page 34.


The Grand Challenges in Global Health (GCGH)

initiative encourages scientists from around the

world to address and overcome some of the

obstacles that block progress against diseases

that affect populations in the developing world.

GCGH represents a major milestone in the

development of the FNIH. Established with the

Bill & Melinda Gates Foundation in 2003, the

partnership not only introduced the largest grant

made to date to the FNIH, but it challenged the

FNIH to broaden its support of partnerships

through functions well beyond fundraising.

Sharing with the Bill & Melinda Gates Foundation

a focus on innovation, feasibility and impact, the

FNIH built new institutional capacity for:

• scientific project and program

management;

• grant making and administration; and

• global health initiatives.

At the organizational stage, for example,

the FNIH:

• managed the “call for ideas,” and processed

more than 1,000 Grand Challenge

suggestions from 75 countries;

• organized and staffed the GCGH Scientific

Board, comprising global health experts

from around the world;

• solicited and reviewed 1,500 letters of

intent containing proposed solutions to the

Grand Challenges; and

• invited and organized peer review for 405

grant proposals.

By 2005, additional partners included the

Wellcome Trust and the Canadian Institutes

of Health Research. The FNIH assumed

ongoing responsibility for both the scientific

and financial oversight of 20 of the original

43 GCGH projects, operating in 25 countries.

FNIH-supported investigators worked to:

• improve upon existing vaccines so as

not to require refrigeration or administration

by needle;

• advance vaccine development through

design of more protective antigens;

• develop biologic, genetic and chemical

strategies to control disease transmission

by insect vectors;

• develop drugs and delivery systems that

minimize the likelihood of resistance; and

• create immunological methods to cure

chronic infections.

Today, six years after their launch, many of these

projects have met their scientific goals and

are delivering promising results in the global

Grand Challenges in Global Health

| 2 0 1 1 A N N U A L R E P O R T10

and Forward

fight against infectious disease. Researchers at

the Rockefeller University, N.Y., for example,

have advanced a new HIV/AIDS prototype

vaccine to clinical trial. Phase 1 clinical

trials have also been approved in India for

a temperature-stable measles vaccine that

can be delivered by the respiratory route.

Even as the initial projects draw to a close,

the FNIH’s role in GCGH continues to evolve.

In 2009, the Bill & Melinda Gates Foundation

provided supplemental funding to extend the

partnership component working to develop

novel control methods against mosquito

vectors of disease. That partnership is known as

Vector-based Control of Transmission: Discovery

Research, or VCTR.

In addition, the FNIH expertise honed through

GCGH has led to several other global health

research partnerships in collaboration with

the NIH, the Gates Foundation, universities,

research institutes and biotechnology

companies around the world.

“Under the GCGH initiative we’ve taken

a completely new concept, in directly

targeting dendritic cells—those

cells that stimulate the immune

system—to work on developing a

vaccine for HIV. Unlike smallpox—

for example—with HIV, natural infection

does not confer durable immunity. If you

are exposed, you could get it again and

again. Our attempt is to achieve

immunity that is better than that

conferred by natural infection with

this novel approach. Our first clinical

trial is virtually finished, with 45 people

receiving the vaccine.”

SARAH SCHLESINGER, M.D. Clinical Study Director, Improved Vaccine Efficacy via Dendritic Cells and Flavivirus Vectors; Associate Professor of Clinical Investigation, Cellular Physiology and Immunology, The Rockefeller University

Vector-based Control of Transmission: Discovery Research Mosquito-borne diseases kill millions of people

every year. Despite recent gains in its control,

malaria remains the biggest killer; at the same

time the incidence of dengue is increasing

dramatically around the world. Absent effective

vaccines, prevention strategies have focused

largely on controlling mosquito populations

and inhibiting disease transmission to humans.

However, as mosquitoes develop resistance to

insecticides, existing approaches are not enough.

Funded by the Bill & Melinda Gates Foundation,

the Vector-based Control of Transmission:

Discovery Research (VCTR) initiative is

managed by the FNIH. It builds on the

promising Grand Challenges in Global Health

research into depleting and/or incapacitating

disease-transmitting mosquitoes. It has three

areas of focus:

Cost-effective and long-lasting biological

control methods

• In 2011, researchers at Imperial College

London and the University of Washington,

Seattle, made a groundbreaking advance

toward a genetic control measure for

mosquitoes that transmit malaria. They

demonstrated that by inserting the gene for

a particular enzyme into a few mosquitoes

and allowing them to mate with standard

(continued on page 12)


mosquitoes, the gene rapidly spreads

throughout an entire laboratory-confined

population. Their next step is to configure

the enzyme to inhibit the mosquitoes’ ability

to reproduce, which would result in fewer

offspring with each successive generation.

• Researchers at the University of

Queensland, Australia, completed a

successful first-round of field trials on a bio-

control agent aimed at eliminating dengue

transmission. The Wolbachia bacterium

inhibits dengue virus development within

the mosquito, and Wolbachia-infected

female mosquitoes readily transmit the

bacterium to their progeny, so the entire

mosquito population should become

incapable of harboring and spreading

dengue. The team confirmed that Aedes

mosquitoes infected with dengue-inhibiting

Wolbachia quickly became established in

two locations in northeastern Australia.

Second-stage trials are underway with

the latest wet season.

Repellents or attractants that exploit or

disrupt the mosquito’s odor receptors

• Specific odor cues emanating from

people help mosquitoes locate them for

a blood meal. Yet, some people are much

more attractive to mosquitoes than others.

Investigators at the Wageningen University

in the Netherlands and at the University

of Colorado, Boulder, showed that the

difference is associated with the kinds

of bacteria that reside on an individual’s

skin. Further study should aid in the

development of new mosquito repellents.

• Teams headed by Larry Zwiebel of

Vanderbilt University and by Richard Axel

of Columbia University have identified

unique molecular components of insect

odorant receptors (ORs). After isolating

and cloning the genes that encode

these ORs, they have expressed them in

mammalian cells. This allows for the facile

screening of hundreds of thousands of

chemical compounds to identify which

ones can activate or inhibit the receptors.

These activators and inhibitors become

the starting point for the development of

new odorant-based products to reduce

disease transmission by mosquitoes and

to control other agricultural insect pests.

Already, a number of the compounds

identified have been found to be effective at

concentrations 1,000 times lower than that

observed with DEET, the most widely used

insect repellent.

Vector-based Control of Transmission: Discovery Research (continued from page 11)

“The Gates-FNIH funding has been

absolutely essential, for it has afforded

the opportunity for us to take

observations in basic neural science

and think about the implications of

those observations for the eradication of

insect-borne human disease. Without this

funding, we would not have the capability

of moving our research in that direction.

The FNIH leadership has been absolutely

seminal in providing their expertise

in insect-borne disease, leading us

scientifically in the right direction,

and in establishing collaborative

partnerships. Put simply—they’ve

been great.”

RICHARD AxEL, M.D.VCTR Investigator; Professor, Howard Hughes Medical Institute, Columbia University; and 2004 Nobel Prize winner in Physiology or Medicine

| 2 0 1 1 A N N U A L R E P O R T12

and Forward

Safer, more effective, and less

expensive insecticides

Current commercially available insecticides target

a very small number of biological mechanisms

in the mosquito. Some compounds are

toxic to humans and are damaging to

the environment; only one class of

compounds—pyrethroids—is approved

for use in treating bed nets. Emerging

resistance to pyrethroids threatens this life-

saving control measure.

To address the urgent need for new insecticides

with novel modes of action, the FNIH issued

a call for research proposals in this area. After

a very competitive review process, it awarded

grants to four projects in 2011:

• Barry Beaty, of Colorado State University, will

utilize nanotechnology to formulate and deliver

insecticidal compounds to the mosquito.

• Jeffrey R. Bloomquist, of the University

of Florida, will interfere with the voltage-

sensitive potassium channel—an important

component of the mosquito’s nervous

system—to develop a new mosquitocide.

• Robert M. Kennedy, of the Vestaron Corp.,

in Kalamazoo, Michigan, will develop small

molecule inhibitors that mimic the properties

of toxic peptides found in spiders.

• Peter M. Piermarini, of The Ohio State

University, will use high-throughput

technology to discover chemicals that

induce “kidney” failure in the malaria

vector Anopheles gambiae.

“What has been different about our

relationship with the FNIH compared

to other funders is their active

involvement in our research program.

They’ve contributed to different issues

and helped us focus our attention on

key issues. They’ve proven to be

invaluable over the last few years.”

SCOTT O’NEILL, Ph.D.Project Leader, Eliminate Dengue project and Faculty of Science Dean, Monash University, Victoria, Australia

Expression of a blue fluorescent protein in tissues of the malaria vector mosquito, Anopheles stephensi. Used by permission N. Xavier, J-M. Sandoval and A.A. James (see Nirmala et al., 2006, Insect. Biochem. Molec. Biol., 36, 694-700. PMID: 16935218).


The HIT-TB project, launched in 2010, is an

FNIH partnership with the Bill & Melinda Gates

Foundation and the National Institute of Allergy

and Infectious Diseases, along with the

Universities of Cape Town, Cambridge and

Dundee. Negotiations are underway with potential

additional pharmaceutical company partners.

This project supports high-throughput

screening of whole Mycobacterium

tuberculosis bacteria using a chemical library

of diverse, high-quality molecules. The goal is

to identify a series of well-characterized small

molecules with defined, tractable bacterial

targets, which potentially could be developed

into drugs against tuberculosis. In its first year,

the project made advances in progressing and

evaluating several HIT series of high interest

from earlier screens.

The Malnutrition and Enteric Diseases Network

(MAL-ED) project, launched in late 2008, is an

FNIH partnership with the Bill & Melinda Gates

Foundation and is co-led by the NIH’s Fogarty

International Center and FNIH. MAL-ED supports

a number of U.S. academic and internationally

based institutions and the U.S. and Thai militaries

to form a network of eight field sites in the

developing world that focus on populations with

high levels of malnutrition and enteric infections.

MAL-ED seeks to improve understanding of

the complex interrelationship between enteric

infections and malnutrition and to describe its

compounding effects on growth, on immune

responsiveness to orally administered vaccines

and on cognitive development in young

children in resource-poor environments. One

of the project goals is to identify vulnerable

periods in early life, and with this knowledge

design better intervention strategies to limit

the risk of mortality and morbidity in children.

Approximately 2,000 children have been

enrolled at birth and are being closely followed

until at least two years of age.

The network is part of a consortium of affiliated

Gates Foundation-funded projects. Although

these projects are not directly managed by

Identification of High-quality HITs for Tuberculosis

Malnutrition and Enteric Diseases Network

The FNIH launches the Genetic Association Information Network (GAIN), a partnership with the National Human Genome Research Institute, Pfizer, Affymetrix, the Broad Institute and other private donors. GAIN was designed to identify the genetic polymorphisms associated with common diseases by conducting genomic studies and making results available to researchers worldwide. The program’s protocols for protecting participant privacy and confidentiality have served as a model for similar studies across the scientific community.

The FNIH launches the Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC), with a grant from the Bill & Melinda Gates Foundation. See page 7.

The FNIH and the National Institute of Mental Health (NIMH) launch the Schizophrenia Metabolic Initiative to evaluate the effects of switching antipsychotic medications to reduce the risk of cardiovascular disease among individuals with schizophrenia.

The FNIH initiates the Biotechnology Resource for Innovation and Development in Genomedicine project, with support from the Avon Foundation and private philanthropists.

The FNIH launches the Biomarkers Consortium, its first partnership aimed at improving clinical and regulatory science, with the NIH, FDA and PhRMA. The Consortium will grow to include a diverse set of projects to qualify biomarkers for use in drug development and clinical care, and attract more than 40 partners from government, industry, academia and nonprofit groups. See page 5.

2006

| 2 0 1 1 A N N U A L R E P O R T14

and Forward

the FNIH, they benefit from collaborating with

MAL-ED investigators and by having access

to MAL-ED resources, data and samples.

These companion projects seek to identify

genetic markers of susceptibility to childhood

malnutrition, to establish the role of the gut

microbiome in malnutrition and susceptibility to

enteric infection, and to identify factors involved

in children’s poor immune responsiveness

to oral polio and rotavirus vaccines in the

developing world.

In 2011, the FNIH received supplemental

funding from the Bill & Melinda Gates

Foundation to participate in additional

sample and data collection for a recently

awarded companion project. The aim is

to determine the effects of the mother’s

microbiome on her child’s endogenous microbial

and physiological development. That project

is contributing to a research pipeline for the

development of protective probiotics.

The Bill & Melinda Gates Foundation also

provided a grant that enabled the FNIH to

organize an international workshop on the

important yet overlooked enteric parasite

Cryptosporidium. The workshop featured updates

on the global burden of this infection, and on

diagnostics and therapeutics, and has provided a

useful framework for future research directions.

“The FNIH and [The Bill & Melinda] Gates

[Foundation] support has made possible

the multicenter study of the suspected

profound lasting effects of early

childhood diarrhea and enteric infections

(with or without diarrhea). It has engaged

top institutions from Asia, Africa and

Latin America and innovative,

state-of-the-art molecular and field

assessments to assess these

lasting effects of intestinal

infections in the first … years of life

on children’s physical growth and

cognitive development.”

RICHARD L. GUERRANT, M.D.Thomas H. Hunter Professor of International Medicine, Director, Center for Global Health, University of Virginia

The FNIH hosts the first Collaborative Summit on Breast Cancer Research in partnership with the Avon Foundation, the American Association for Cancer Research, the American Cancer Society, The ASCO Foundation, The Breast Cancer Research Foundation, the National Breast Cancer Coalition Fund, the Polo Ralph Lauren Foundation/Pink Pony, Susan G. Komen for the Cure and the National Cancer Institute.

2007

The first O’Neill Fellow makes an important discovery in genetic mechanisms found in 50 percent of all kidney cancer patients. This discovery, made by Dr. Nanae Harashima and the team of doctors in Dr. Richard Childs’ lab, leads to new treatments to stem the cancer’s spread and gives new hope for a cure.

CRTP holds a 10-year reunion, gathering graduates of the program and their former tutors and mentors on the NIH campus for a two-day workshop and celebration.

The FNIH receives its first four-star rating from Charity Navigator and is also named to the top 400 Charities List by the Chronicles of Philanthropy. It receives both honors again in 2008, 2009, 2010 and 2011.

ADNI completes enrollment of 823 participants and begins collecting and analyzing data.


Eight years after its initial launch, the


(ADNI) has produced numerous adjunct and

follow-up studies that are not only advancing

understanding of this devastating disease,

but changing the way scientific research is

conducted worldwide.

The program was conceived by the National

Institute on Aging which provides the public

support, and the FNIH providing support

from the private partners, with the goal of

encouraging collaboration by a wide array

of researchers in academia and industry.

To do that, the initiative had to first solve the

problem of standardizing collection of different

types of research data. It established detailed

protocols for enrolling patients in the study

and for collecting and assessing the clinical/

neuropsychological, neuroimaging,

and other biomarker tests and measures used

to track disease progression over time. Next,

it created an open database, where data could

be uploaded and downloaded as they were

generated. This enabled researchers around the

world to access, share and compare data and


“With its unique ability to creatively

connect private and public-sector

institutions, the Foundation for the

NIH has been an essential partner in

this important initiative.”

NEIL BUCKHOLTZ, Ph.D.Chief, Dementias of Aging Branch, Division of Neuroscience, National Institute on Aging

| 2 0 1 1 A N N U A L R E P O R T16

and Forward

findings quickly, even before publication

of papers. The net effect is a significant

acceleration of critical, and otherwise

expensive, research.

The model’s success has won over skeptics,

attracting additional funding and participation.

As a result, the launch of ADNI 2 is enabling

researchers to:

• track the study’s initial control and mild

cognitively impaired patients for another

five years;

• enroll 1,200 new individuals, some of

who present with early mild cognitive

impairment; and

• add new imaging techniques for detecting

the progression of Alzheimer’s disease.

Because of the success of ADNI, and through

the efforts of the Alzheimer’s Association,

ADNI is becoming a worldwide initiative with

programs utilizing the standards and protocols

developed here. Initiatives are currently

ongoing in Denmark, France, Germany,

Italy, the Netherlands and Sweden through

European ADNI; from Japan through J-ADNI;

from Australia through the Australian ADNI;

from South Korea through K-ADNI; and from

Taiwan through TW-ADNI. Argentina, China and

Thailand are in the discussion stages of joining

World Wide ADNI. Together, these efforts are

creating a substantial dataset no one entity

could amass on its own, and, thanks to its

open nature, a legion of scientists working to

decipher its clues.

“Although it may not have been fully

appreciated initially, the degree of

academic, government and industry

engagement in ADNI paved the way for

the principle of a successful

precompetitive consortium. ADNI

brought together a number of AD

investigators and industry leaders, all in

strong support of its overall concept and

goals. In hindsight, it is remarkable to note

how potential competitors in the pursuit

to develop drugs for AD joined forces and

are now committed cooperators together

with academic centers, under the auspices

of NIA and the FNIH.

When ADNI now, after eight years, has

completed ADNI 1 and is now well into

ADNI 2, through the stepping stone of the

ADNI-GO grant, one can not only reflect

on the value of ADNI as a critical effort to

better understand AD pathophysiology

and the progression of this devastating

disease, but also on the fundamental

importance ADNI has on the design of

innovative therapy trials. Although the

outcome of current industrial efforts

remains unclear, ADNI provides a critical

scientific platform for the execution of

such endeavors, and by this brings hope

to patients and caregivers that better

treatment options will emerge.”

JOHAN LUTHMAN, D.D.S., Ph.D.Chair, ADNI 2 Private-Partner Scientific Board; Senior Program Leader, Neuroscience & Ophthalmology R&D, Franchise Integrator, Merck & Co.


While the incidence of Chronic Obstructive

Pulmonary Disease (COPD) is increasing sharply

in the U.S., a cure remains out of reach for this

progressive and debilitating condition. The

SubPopulations and InteRmediate Outcome

Measures in COPD Study (SPIROMICS) is laying

the groundwork for clinical trials that could

speed development of effective therapies.

Supported by the FNIH and six private sector

partners, National Heart, Lung and Blood

Institute is collecting and pooling lung function,

imaging and biochemical data from more than

3,000 COPD sufferers and controls over three

years. These data will allow scientists to better

categorize patients according to their specific

COPD profile, which in turn should help them

tailor potential therapies to those most likely

to benefit.

At the same time, researchers will scrutinize the

data to identify more precise measures of the

disease’s progression. This will enable them to

more quickly assess whether an experimental

therapy is working.

The study is being conducted over seven

years at six academic clinical centers across

the United States.

SubPopulations and InteRmediate Outcome Measures in COPD Study

“The concept at NHLBI was to engage the

Foundation for the NIH to in turn engage

private industry. In fact, private industry is

now extremely enthusiastic about this

project, as is the FDA.

The FDA said it specifically wanted more

information about a certain aspect—

COPD exacerbations. So we revised the

protocol with input from the FDA and

industry partners, and now it’s a much

better protocol, scientifically, as a result.

And industry partners can easily see the

added value of doing these experiments.

This absolutely would not have been

possible without the Foundation for the

NIH—they created the forum for

discussion among all sectors, which

actually is the most important thing.

And they brought in the financial

contributions.”

STEPHEN RENNARD, M.D.Chair, SPIROMICS Steering Committee; Larson Professor of Medicine, University of Nebraska Medical Center

| 2 0 1 1 A N N U A L R E P O R T18

and Forward

Human Papilloma Virus Clinical TrialThe National Cancer Institute (NCI) HPV-16/18

Vaccine Phase 3 Trial in Costa Rica completed

four years of follow-up on its 7,466 randomized

participants in 2011. Results from the trial

indicated high efficacy of the vaccine against

new infections with human papilloma virus (HPV)

types included in the vaccine and partial protection

against new infections caused by several other

HPV types (types 31, 33 and 45) that are closely

related to HPV-16/18. HPV is the most common

sexually transmitted infection, and HPV-16/18 is

responsible for an estimated 70 percent to 80

percent of all cases of cervical cancer worldwide.

The vaccine used in the Costa Rica trial was

manufactured by GlaxoSmithKline (GSK)

Biologicals. With an infusion of $6 million in

additional funding via the FNIH, investigators

at NCI were able to ensure that validation and

regulatory aspects of the trial were incorporated

so that the data could be included as part of

the FDA Investigational New Drug (IND) held

by GSK Biologicals. Submission of the final IND

report is pending.

Funding such programs is an important way

the FNIH helps translate scientific research and

development into real health improvements in

people’s lives.

Research Partnership in Cognitive AgingScientists throughout the country met in

October 2011 to discuss their latest findings

on changes in brain function and behavior

associated with normal aging. The researchers

are grant recipients from the Research

Partnership in Cognitive Aging, an FNIH initiative

with the National Institute on Aging and the

McKnight Brain Research Foundation. The

program aims to expand understanding of how

people think, learn and remember with age, and

to develop interventions to maintain cognitive

health as they grow older. Altogether, the

$28 million partnership is funding 17 different

research projects over the course of five years.

Neuro-Oncology Branch FundDespite important advances in imaging,

neurosurgery and radiation, the prognosis for

patients with the most common type of primary

brain tumor has improved very little over the

past 20 years. Most patients survive less than

a year after diagnosis. A joint program of the

National Cancer Institute and the National

Institute of Neurological Disorders and Stroke,

the Neuro-Oncology Branch was established

to develop a new, nontraditional approach to

fighting primary brain and central nervous

system cancer.

In 2011, the FNIH launched its Neuro-Oncology

Branch Fund to support this effort, which

focuses on biology-driven, individualized

therapeutics. Centralizing patient care has

enabled the branch to amass a vast tissue

database for laboratory research and a large

patient population from which to draw for

clinical trials. The branch also hosts one of

the few neuro-oncology fellowship-training

programs in the United States.

Already the branch has made notable strides,

including the activation of 11 clinical trials and

the identification of a dozen compounds worthy

of clinical testing.


and Forward

Training and Education

| 2 0 1 1 a n n u a l r e P o r t20

The Bernard Osher Foundation/NCCAM Complementary and Alternative Medicine Practitioner Research Career Development AwardIn partnership with the National Center for

Complementary and Alternative Medicine (NCCAM)

at the NIH, the Osher Foundation provides

support for NCCAM fellowships to individuals

studying complementary and alternative medicine.

Through this program, established in 2006,

awardees receive up to five years of intensive,

supervised career development research training in

biomedical, behavioral or clinical sciences related to

complementary and alternative medicine.

Principles of Clinical PharmacologyThrough a partnership established in 2008, the

PhRMA Foundation helps to broaden the reach of

the NIH’s Principles of Clinical Pharmacology course.

The course fills a significant void, as most medical

schools do not offer a formal course in this field.

The lecture series, which runs from September

through April, is taught by faculty from the NIH, the

FDA, the pharmaceutical industry and academic

institutions across the country. In 2011, the course

attracted a record 1,196 students—physicians,

pharmacists and other scientists. About a third

attended the lectures at the NIH campus, with the

rest participating via teleconference from 24 remote

sites in the U.S. and abroad.

The course teaches the pharmacologic aspects of

drug development and use in therapeutics, preparing

trainees for the certification exam of the American

Board of Clinical Pharmacology.

Sayer Vision Research LectureNapoleone Ferrara, M.D., Ph.D., a Fellow at

Genentech, Inc., delivered the fifth Sayer Vision

Research Lecture at the NIH in June 2011. Ferrara’s

address was entitled, “Basic Science and Clinical

Application of VEGF.”

Early in his career, Ferrara played a key role in

isolating and cloning vascular endothelial growth

factor (VEGF), a protein that stimulates formation of

new blood vessels. He identified the protein’s role in

abnormal vessel growth in eye diseases such as wet

age-related macular degeneration (AMD), a leading

cause of vision loss in older Americans. Building on

that research, his laboratory developed an anti-VEGF

antibody fragment, which can significantly improve

sight in wet AMD patients and limit further vision

loss. This work earned him the 2010 Lasker-DeBakey

Clinical Medical Research Award—one of the most

prestigious awards in science.

The Sayer Lecture is supported by the Sayer Vision

Research Fund at the FNIH. See page 33.

Just as vital as fundamental laboratory work in advancing biomedicine, training

and education programs must be robust and accessible to equip and inspire the

next generation of young scientists. Through its support of lectures, coursework,

internships, fellowships, residencies and scholarships, the FNIH helps to ensure

that the progress of biomedical research continues apace. The FNIH funding

often can expand substantially the reach of training programs by affording

videoconference and remote-site linkages.


Clinical Research Training CourseModeled after a long-running course at the NIH Clinical

Center, the first Clinical Research Training Course

was held at the Kulakov Federal Research Center for

Obstetrics, Gynecology and Perinatology in Moscow in

November. A component of the U.S.-Russia Scientific

Forum, the course was taught by Clinical Center

Director John I. Gallin, M.D., and other NIH faculty.

Entitled “Principles and Practice in Clinical Research,”

the five-day course featured lectures on clinical trial

best practices, orphan and rare diseases, ethics,

research integrity, data safety monitoring, data

analysis and more. The approximately 220 Russian

participants were chosen from a broad range of

medical specialties.

Planning is underway for the year two course,

which will focus on pharmacology.

Laboratory Animal Medicine Resident Training ProgramThe NIH, through the Division of Veterinary

Resources and the National Heart, Lung and

Blood Institute, has developed the Laboratory

Animal Medicine Resident Training Program.

This program prepares laboratory animal

veterinarians and develops a resource

of specially trained laboratory animal

veterinarians for the NIH intramural research

program as well as the entire laboratory animal

and research community.

Thanks in part to SoBran and its generous

contribution, the program has enrolled its first

resident trainee, Tannia Clark, D.V.M. Clark is currently

participating in a multi-disciplinary rotation over

the course of two years, including didactic training

classes, exposure to the mouse imaging facility, study

of the laws and regulations of animal research and

development of a research project. This training will

prepare Dr. Clark for the certification examination for

the American College of Laboratory Animal Medicine.

“The Laboratory Animal Medicine

Residency Training Program is an exciting

opportunity for me. It has allowed me to

explore the world of laboratory animal

medicine and biomedical research.

Currently, I am in my clinical rotations

and I have enjoyed the challenges of

keeping my ‘patients’ healthy and happy.

My mentors have provided me the

opportunity to understand and improve

the health and welfare of my animal

patients, while supporting investigators

with the best research opportunity.

After successful completion of this

residency, I hope to join the ranks of

ACLAM (American College of Laboratory

Animal Medicine) board-qualified

veterinarians and support the

advancement of biomedical research

with a continued emphasis on

animal welfare.”

TANNIA CLARK, D.V.M.Laboratory Animal Medicine Resident, National Institutes of Health

| 2 0 1 1 A N N U A L R E P O R T22

and Forward

“I remember the moment I was awarded

the Newcomb scholarship, the grant that

would allow me to work in a cutting-edge

neuroendocrinology lab at the National

Institutes of Health. After jumping up and

down appropriately, I called my parents,

mentors and extended family to share the

news. Everyone, like me, was excited and

awed—it was a dream come true. I uprooted

myself from my Pacific Northwest home and

trekked out to Washington, D.C., to embark

on this grand adventure.

Ultimately, the shift from thinking like a

college student to thinking like a scientist

has been challenging, rewarding and truly

meaningful. I am actually doing science, not

just learning about it in a classroom.

Furthermore, these skills directly prepare me

for future career aspirations: namely,

medical school and beyond.

First and foremost, researching at

the National Institutes of Health has

confirmed that this is the career for

me. I’m deepening my abilities as a

scientist, my respect for the community, and

the confidence to continue as a professional.

To be given the opportunity to live in such an

exciting place and to develop as a researcher

is truly remarkable: I try to take advantage of

every second.”

SARAH SHANGRAW2011–2012 Robert Whitney Newcomb Fellow


Other ProgramsADAS Cog

Age-Related Eye Disease Study Genetic Repository Toxicity Study of Buprenorphine/Naloxone

Burkitt Lymphoma Genome Sequencing Project

Congenital Adrenal Hyperplasia

Cancer Research Fund

Clinical Investigator Student Training Forum

Clayton-Dedonder Scholarship Awards

Clinical Center In-Kind Drug Donation Program

Drug Induced Liver Injury Network

Epigenetic and Immunoregulatory Control of Ocular Inflammatory Disease

Evaluation of the Effect of Negative Costimulatory Signals on the Model of Experimental Autoimmune Uveitis Using the Ig Fusion Construct AMP-110

Development and Production of Endotoxin under GMP for Human Clinical Research

Frequent Hemodialysis Project

Google Ad Grant for Parkinson’s Disease Research

Hereditary Hyperhomocysteinemia

Human Genome Exhibition

Human Microbiome Project Demonstration Projects

I Can Do It, You Can Do It

“A major component of the Clinical

Center’s vision is to lead the global

effort in training today’s investigators.

Through a generous donation to the

Foundation for the NIH from Eli

Lilly, we were able to offer the

Clinical Center’s “Introduction

to the Principles and Practice of

Clinical Research” course in

Moscow for the first time in

November 2011. About 220 students

participated in the course, which was

presented at the Kulakov Federal

Research Center for Obstetrics,

Gynecology and Perinatology in

Moscow. A second course, “Principles

of Clinical Pharmacology,” will be

offered in Moscow in 2013. FNIH

support is allowing us to have both

textbooks translated into Russian,

which will be a tremendous resource

for our colleagues there.”

JOHN I. GALLIN, M.D.Director, Clinical Center, National Institutes of Health

The first Cognitive Aging Summit takes place with support from the McKnight Brain Research Foundation and NIA. The summit identifies recommendations for research directions, ultimately leading to the Research Partnership in Cognitive Aging. The partnership, coordinated by the FNIH, funds 17 research grants totaling $28 million. See page 19.

with initial funding from Diet Coke, the FNIH establishes The Heart Truth® Community Action Program in partnership with the NHLBI to promote women’s heart health.

GAIN ends, having mapped the genotypes and phenotypes of 18,000 samples and posts them to the National Library of Medicine database of Genotypes and Phenotypes.

The FNIH receives a grant from the Bill & Melinda Gates Foundation to establish the Malnutrition and Enteric Diseases Network (MAL-ED). See page 14.

2007

The Observational Medical Outcomes Partnership (OMOP) begins. The first project of its kind, OMOP conducts methodological research for active safety surveillance of drugs already on the market. See page 9.

2008

The FNIH hosts the inaugural mHealth Summit. See page 27.

2009

| 2 0 1 1 A N N U A L R E P O R T24

and Forward

Other Programs (continued from page 24)

Induced Pluripotent Stem Cell Consortia

Measures for Clinical Trials of Treatment of Cognitive Impairment

Mutational Analysis of the Melanoma Genome

Neurotropin Research Project

NIH Medical Research Scholars Program

Osteoarthritis Initiative 2

Overcoming Barriers to Early Phase Clinical Trials

Oxford-Cambridge Scholarship Program

Oxford-Cambridge Colloquium

Pain and Palliative Care Program, Roxane Institute

PATH: Physical/Psychological Advocacy & Treatment for HIV Youth Program

Pew Latin American Fellows Partnership

Post-doctoral Fellowship in Molecular Imaging and Nanomedicine

Progressive Multifocal Leukoencephalopathy Data Registry

Edmond J. Safra Family Lodge

Schizophrenia Metabolic Initiative

Senior Independent Living Research Network

Smoldering Multiple Myeloma

T-Cells & AMD

T Regulatory Cells as a Peripheral Marker for the Development of Age-Related Macular Degeneration and Uveitis

Tracking Intracellular Nanoparticle Dynamics and Cytotoxic/Epigenetic Signatures both in vitro and in vivo Using Advanced Cytometry and Multimodal Imaging

Undiagnosed Diseases Program

Vaccine Research Center’s Community Advisory Board

The FNIH introduces new brand.

Celebrities Bill and Giuliana Rancic participate in the 4th Annual Boo! Run For Life 10K run and two-mile Tidal Basin walk in washington, D.C., to raise awareness and funds for kidney cancer research. The event is organized by friends and family of Dean R. O’Neill.

The FNIH receives a grant from the CVS Caremark Charitable Trust to establish the I Can Do It, You Can Do It community grant program to promote physical fitness for children with disabilities.

The FNIH receives grants from the Bill & Melinda Gates Foundation for the Vector-based Control of Transmission: Discovery Research initiative and the Centralized Envelope Comparative Immunogenicity Phase I Trial. See pages 8 and 11.

Results of the Biomarkers Consortium’s first completed project—that a protein, adiponectin, is a predictive marker for Type 2 diabetes —are published in Clinical Pharmacology and Therapeutics.

The MAL-ED project establishes harmonized protocols and begins enrolling infants into the study at eight sites in Africa, Asia and South America.

The FNIH awards the first The Heart Truth® Community Action Program grants. See page 28.

The FNIH partners with pharmaceutical companies to secure in-kind drugs for the NIH Clinical Center pharmacy.

2010


Beyond the conferences and symposia that are the workhorses of scientific

information transfer, events have come to play a vital role in biomedical

research—attracting nontraditional partners and funders to research

initiatives and engaging the public in disease and health awareness.

Acknowledging the power of networking and dialog in its various forms,

the FNIH supports all manner of events, from career fairs to exhibits,

receptions and media opportunities.

Events

| 2 0 1 1 A N N U A L R E P O R T26

mHealth Summit December 5–7, 2011, Washington, D.C.

In many ways, the mHealth Summit is emblematic

of the work of the FNIH as a whole. Inaugurated

in 2009, the summit was conceived as a vehicle to

converge two complex and fast-changing industries—

medical science and telecommunications—to

improve and even revolutionize health care delivery

worldwide. To truly tap the potential of this alliance,

the FNIH and its mHealth founding partners

brought together not only scientists and technology

experts, but entrepreneurs, scholars, practitioners,

policymakers and others to map the new future

of public health care.

With the mHealth field still in its infancy, the first

summit sparked immediate interest and enthusiasm,

attracting 800 attendees from 25 countries. In the

two years since, it has grown dramatically—bringing

thousands of attendees, hundreds of exhibiting

companies, visionary leaders such as Bill Gates and

Ted Turner, and workable, on-the-ground solutions

to health care delivery.

In 2011, the summit moved to Washington, D.C.’s

Gaylord National Resort and Convention Center to

accommodate the burgeoning crowd, exhibitors and

pavilions. In addition to super and special sessions, it

offered 14 education tracks in the areas of business,

policy, research, technology, mFinance and end-

user solutions. Keynote speakers over the four

days included U.S. Secretary of Health and Human

SPONSORS

ORGANIZING PARTNERS

Services Kathleen Sebelius, Qualcomm Chairman

and CEO Paul E. Jacobs and Federal Communications

Commission Chairman Julius Genachowski.

The mHealth Summit has become the defining event

for this fast-paced industry, and continues to grow

in scope and sophistication. As producer, the FNIH

is helping to vastly accelerate the pace of delivering

quality, cost-effective health care to even the most

remote corners of the world.

mHEALTH SUMMIT | Annual Growth

2009 2010 2011

19

2400

7

700

16

3600

Attendees Sponsors


The Heart Truth® Red Dress Collection Fashion Show 2011February 9, 2011, New York, New York

Each February since its launch, The

Red Dress symbol has come to life

on the runway with the support of

the fashion industry and celebrity

models at the Red Dress Collection

Fashion Show.

This high-profile event at the Mercedes Benz

Fashion Week is a signature part of The Heart Truth®

campaign, an initiative of the National Heart, Lung

and Blood Institute of the NIH. For the past decade,

it has raised awareness of heart disease as the

number-one killer of women in America. The

campaign’s symbol is the Red Dress. Since

2008, the Foundation for the NIH has helped

spread The Heart Truth® message through its

support of this event, as well as fund a community

action program which awards grants to organizations

across the country promoting women’s heart health.

In 2011, the FNIH awarded grants totaling $200,000

to seven organizations, targeted especially at

minority and underserved communities. Initiatives

include free health screenings; activities promoting

stress reduction, nutrition, exercise and emotional

health; interactive websites; and training for

outreach volunteers.

SPONSORS

“The Heart Truth grant made it possible

for Wheaton Franciscan-St. Joseph to

provide community outreach and

education on women and heart disease

to African American women and the

impact was tremendous. Through our

grant-supported efforts, we armed

women with heart disease facts and

they took action for self-improve-

ment by getting the recommended

health care screenings, eating

healthier and increasing their

physical activity.”

ROSHA L. HAMILTON, R.N., M.S.W. Director Community and Patient Health Education Services, WheatonDirect Wheaton Franciscan Healthcare, Glendale, Wisconsin

Photo courtesy of The Heart Truth’s Red Dress Collection

Wheaton Franciscan-St. Joseph in Glendale, Wisconsin hosts a chef demonstration featuring heart healthy cooking.

| 2 0 1 1 A N N U A L R E P O R T28

and Forward

International Human Microbiome CongressMarch 9–11, 2011, Vancouver, British Columbia

Attention is increasingly being focused on the

human microbiome—the microbial species that

reside on and within the human body—as a means

to understanding health and disease. This meeting,

organized by the FNIH, attracted more than 400

participants worldwide. Researchers from the

medical, microbial and computational fields convened

to discuss the complex relationships between the

microbiome and the human body, and were joined

by food and pharmaceutical industry representatives,

science reporters and funders.

The congress explored not only current findings

in the field, but also ethical, legal and social

implications of the research and new technologies

and computational tools to aid in the study.

National Institute of Arthritis and Musculoskeletal and Skin Diseases 25th Anniversary Scientific Symposium—Improving Lives Through DiscoveryJune 13, 2011, Bethesda, Maryland

NIAMS used the occasion of its 25th anniversary to

host a symposium highlighting its accomplishments,

challenges and future direction. It attracted a wide

range of stakeholders—including the scientific

community, volunteer and professional organizations,

patients and congressional staff—to address the

scientific advances and the improvement to patients’

lives made possible with NIAMS support.

The symposium, supported by the FNIH, featured

a broad array of presentations—scientific sessions

from outstanding junior and senior researchers,

reflections on the importance of mentors and

training, and inspirational patient testimonials on how

such research has affected their lives and families.

A dinner presentation, “Bringing Medicine and

Science to the Public,” featured National Public

Radio host Diane Rehm.

SPONSORS

Saving You Time For Life

SPONSORS

The Honorable John and Amy Porter


JAK-STAT Pathway: Twenty Years from Discovery to DrugsSeptember 22–24, 2011, Bethesda, Maryland

Discovered 20 years ago, the JAK-STAT pathway is

a complex biochemical mechanism for transmitting

information across a cell membrane and into the

nucleus to spur various activities. This pathway has

shed light on a number of diseases—from immune

deficiencies to hematological malignancies—and

the NIH holds the patent for exploiting it in search of

new immunosuppressive agents.

Many pharmaceutical firms have since targeted

this pathway in their efforts to develop a new class

of drugs. This meeting, organized by the FNIH,

brought together industry scientists to present their

most recent work and to spotlight the translational

advances that have been made.

U.S.-Russia Collaboration in the Biomedical Sciences—Forum MeetingNovember 16–18, 2011, Moscow, Russia

Organized by the FNIH at the behest of the U.S.-

Russia Bi-Lateral Presidential Commission, this

high-level forum was designed to encourage broader

collaboration in biomedical and behavioral research

between the two countries. Partners included the

NIH, the Institute of Medicine, the Russian Academy

of Medical Sciences and the Russian Academy of

Sciences.

The three-day meeting featured distinguished

researchers from the United States and the Russian

Federation and focused around five agendas: cancer,

active and healthy lifestyles, human development, rare

diseases and infectious diseases. A complementary

meeting, concerning brain sciences, was held at the

NIH campus in Bethesda, Maryland.SPONSORS

FOUNDING PARTNER SPONSORS

Cheerful music brought joy to scores of patients, families

and staff at the NIH Clinical Center on December 20, 2011.

For the seventh year in a row, acclaimed composer Marvin

Hamlisch delighted guests at a holiday concert held on the

NIH campus. He was joined this year by Broadway actor and

vocalist Gary Mauer. Each year, Hamlisch performs at the

NIH as a tribute to his friend Lily Safra and her late husband

Edmond. Mrs. Safra is a longtime benefactor to patients and

their families undergoing treatment at the Clinical Center,

having provided the leadership gift to the FNIH to build the

Edmond J. Safra Family Lodge on the NIH grounds.

Marvin Hamlisch in Performance at the Family Lodge

| 2 0 1 1 A N N U A L R E P O R T30

and Forward

Ecology and Evolution of Infectious DiseasesMarch 26–29, 2011SPONSOR

U.S.-Russia Forum Planning MeetingApril 24–25, 2011SPONSORS

4th Annual NIH Career SymposiumMay 10, 2011SPONSOR

NINR-NIH Clinical Center Joint ConferenceMay 12, 2011SPONSOR

Alzheimer’s/Dementia Outcome Measures MeetingMay 24, 2011SPONSORS

NIH/FDA Glycosciences Research DayJune 15, 2011SPONSORS

4th Annual NIH Graduate and Professional School FairJuly 22, 2011SPONSOR

NINR—Science of Compassion— End of Life SymposiumAugust 10–12, 2011SPONSOR

NHLBI Genomics SymposiumSeptember 12–13, 2011SPONSOR

NIH Director’s Pioneer Award Symposium and Award ReceptionSeptember 20, 2011SPONSORS

Symposium on Cardiovascular Regenerative MedicineOctober 4–5, 2011SPONSORS

NINR Concluding Scientific SymposiumOctober 13, 2011SPONSOR

NCMRR 20th Anniversary SymposiumDecember 12–13, 2011SPONSORS


FUNDS AND ENDOWMENTS

ESTABLISHED AT THE FNIH ARE

A LASTING WAY FOR INDIVIDUALS

AND ORGANIZATIONS TO PAY

TRIBUTE TO SPECIAL PEOPLE OR

CAUSES THROUGH ONGOING

SUPPORT OF RESEARCH,

EDUCATION OR EVENTS IN

BIOMEDICINE AT THE NIH. LARGE

OR SMALL, SUCH GIFTS ARE

A TESTAMENT TO THE IMPACT

EVERY PERSON CAN MAKE ON

DISCOVERIES THAT ADVANCE

HUMAN HEALTH.

| 2 0 1 1 A N N U A L R E P O R T32

and Forward

Named Funds Named funds are created to support specific areas

of research or fellowships, lectures or awards at the

National Institutes of Health.

Gramlich Melanoma Research FundThe Gramlich Melanoma Research Fund supports

melanoma research at the NIH through an annual gift

provided by the Jack Gramlich Foundation.

NIH Director’s Initiative FundEstablished in 2008 in honor of Dr. Elias Zerhouni,

who served as the NIH Director from May 2002

through October 2008, the fund supports special

initiatives of importance to current and future NIH

Directors and scientists.

Sayer Vision Research FundThe Sayer Vision Research Fund supports an annual

lecture delivered by an investigator in the area of

vision research. The fund also supports the Sayer

Vision Research Award, a grant-in-aid to support the

research of a promising independent investigator, in

the early stage of his or her research career in the

Division of Intramural Research at the National Eye

Institute. The fund was established by NIH research

scientist Jane Sayer, in honor of her family and in

memory of her parents, Winthrop and Laura Sayer.

Swanson Family FellowshipThe Swanson Family Fellowship supports research

in TTF-1 mutation-causing benign chorea in the

laboratory of infectious diseases under the direction

of Steven M. Holland, M.D., Chief of the Laboratory of

Clinical Infectious Diseases at the National Institute of

Allergy and Infectious Diseases at the NIH.

Memorial FundsMemorial funds create a living legacy. In many

cases, a family member may request that friends

and relatives make donations—rather than send

flowers—to support a chosen cause in memory of a

loved one. Families may wish to go one step further

and establish a fund that embodies a loved one’s

passion and spirit by making a significant investment

in the Foundation.

Dr. John L. Barr Memorial FundThe Dr. John L. Barr Memorial Fund helps to

support the Intramural Research Training Award

Fellowship Program at the NIH Clinical Center’s

Pain and Palliative Care Service. The objective

of the fellowship is to conduct research on pain

and palliative care, and also to encourage young

investigators to become more familiar with the

importance of this field of study.

Adam J. Berry Memorial FundThe Adam J. Berry Memorial Fund was established

by Michael and Sue Berry in memory of their

beloved son, Adam. Adam came from Australia to

work as a research scientist at the National Cancer

Institute. The fund commemorates his life and

his enthusiasm for work by making it possible for

promising young Australian scientists to travel to the

United States and work at the NIH.

Edna Williams Curl and Myron R. Curl Fund for Multiple Sclerosis ResearchThe Edna Williams Curl and Myron R. Curl Fund,

established in 2007, supports multiple sclerosis

research at the National Institutes of Health.

Funds and Endowments


John Laws Decker Memorial FundA former Director of the NIH Clinical Center,

Dr. John Laws Decker strived to connect

research communications around the world to

exchange information and accelerate important

scientific research. His dedication to education

and communication about science led the NIH

to establish an annual lecture in his name. This

fund, established by the Decker family, supports

a small event for the lecturer each year.

Dean R. O’Neill Renal Cell Cancer Research FundThe Dean R. O’Neill Renal Cell Cancer Research

Fund supports a fellowship in the laboratory of

tumor immunology headed by Richard Childs, M.D.,

of the National Heart, Lung and Blood Institute.

The postdoctoral cancer investigator funded by

the program conducts research on the treatment

of renal cell (or kidney) cancer. The 2011 Rancic-

O’Neill Fellow was Quinn Weisman.

Family and friends of the late Dean O’Neill

established the fund. More information can be

found at www.renalcellcancer.org. The family

also organizes the annual Boo! Run for Life 10K race

and two-mile walk to support the fund. Information

about the Boo! Run, held annually in October, can

be found at www.boorunforlife.com.

Dr. Edward T. Rancic Memorial FundThe Dr. Edward T. Rancic Memorial Fund supports

a post-doctoral fellowship that focuses on renal

cell cancer research in the laboratory of tumor

immunology headed by Richard Childs, M.D., of

the National Heart, Lung and Blood Institute. The

fellowship was established in memory of Dr. Edward

Rancic by his family. The 2011 Rancic-O’Neill Fellow

was Quinn Weisman.

Dr. Anita Roberts Memorial FundDr. Roberts was one of the first female laboratory

chiefs at the NIH and ranked in the top 50 most-

cited biological scientists in the world. She was

widely recognized as an outstanding mentor,

encouraging and inspiring young scientists. In

recognition of her commitment to mentoring, Dr.

Roberts’ family and lab colleagues established

scholarships to allow graduate students and post-

doctoral fellows to present their work at a national

meeting. Two travel scholarships are awarded to

the TGF-beta Keystone Symposium held every

other year. These scholarships are a fitting tribute

to Dr. Roberts’ passion for encouraging the career

development of young scientists.

If you are interested in establishing a fund or endowment at the FNIH,

and making a significant investment and impact on a disease that is important

to you or a loved one, please contact Caite Gilmore at 301-594-2612 or

[email protected].

| 2 0 1 1 A N N U A L R E P O R T34

and Forward

Tracy’s Toy BoxEstablished by the family in memory of Tracy

Nadel, the Tracy’s Toy Box Fund purchases toys and

activities for children staying at the Edmond J. Safra

Family Lodge. These items aim to help make their

time at the Lodge more comfortable and pleasant.

Robert Whitney Newcomb Memorial FundThe Robert Whitney Newcomb Memorial Fund

was established by the family to remember Dr.

Newcomb, who began his scientific career at the

NIH as a high school summer intern in a laboratory

at the National Cancer Institute. The fund endows

an annual lecture by a recognized expert in

neuroscience, selected by the National Institute

of Neurological Disorders and Stroke (NINDS).

Honoring Dr. Newcomb’s own experience, it also

provides for internships for high school students and

fellowships at NINDS.

Stephen J. Solarz Memorial FundThe Stephen J. Solarz Memorial Fund was established

by Nina Solarz in memory of her husband, former

Congressman Steve Solarz, to support the research

of Dr. David Schrump at the National Cancer Institute.

Dr. Schrump’s pioneering research in the field of

thoracic oncology led to the treatments that allowed

Steve to live years beyond what otherwise would

have been possible. Before he died, Nina and her

family dedicated themselves to supporting Dr.

Schrump’s research so that other patients might

benefit from even better treatments.

Over the course of two years, the Solarz’s friends

and family contributed more than $240,000 to

support this important research in Steve’s memory.

In 2011, the Solarz Fund enabled Dr. Schrump to

begin research aimed at developing a cancer vaccine

for all types of cancer. The fund supported research

that manipulates DNA in cells taken from a patient’s

tumor to produce molecules that will stimulate the

immune system to kill cancer cells. In this way, Dr.

Schrump creates a vaccine from a patient’s own

tumor cells—a “personalized cancer vaccine.”

The Solarz Fund also supported development

of another kind of vaccine that can be used to

immunize cancer patients if their tumor cells do not

grow sufficiently to make a personalized vaccine.

Dr. Schrump now plans to enroll participants in the

vaccine trial.

Stephen E. Straus FundEstablished by Bernard and Barbro Osher in 2006,

this fund honors the founding director of the NIH’s

National Center of Complementary and Alternative

Medicine (NCCAM), the late Dr. Stephen E. Straus.

It supports the Stephen E. Straus Distinguished

Lecture in the Science of Complementary and

Alternative Medicine, an annual lecture that brings

leading figures in science and medicine to the NIH

to speak about their perspective on the field of

complementary and alternative medicine. Open to

the public, the lecture is videocast and archived on

the NCCAM website.

“The lodge is beautiful and it’s been amazing staying here. It was very inviting to walk into the lodge. It’s been the best place I have stayed.”

“Everything was great. I am most grateful to have been a guest.”

“The comfort. Being able to relax by the fire or sit and visit over coffee in the kitchen. And to be able to walk to the [Clinical Center].”

Safra Lodge Guests


Endowments Through endowment gifts, donors ensure perpetual

support for a variety of research and educational

initiatives at the Foundation for the NIH. The annual

investment income generated by an endowment

fund supports program expenses, while the principal

remains intact to ensure future funding.

Sallie Rosen Kaplan Fund for Women Scientists in Cancer ResearchThe Kaplan Fund, established in 2000, provides support

for the Sallie Rosen Kaplan Fellowships for Women

Scientists in Cancer Research. These post-doctoral

fellowships are awarded to one or more outstanding

female scientists at the National Cancer Institute.

Norman P. Salzman Memorial FundDr. Norman P. Salzman’s family, colleagues and

friends remember the legacy of this noted pioneer

in molecular biology through contributions to the

Salzman Memorial Fund, which supports the annual

Norman P. Salzman Memorial Award and Symposium

in Virology. The half-day symposium addresses key

topics in virology and immunology and presents an

award to a young researcher, in recognition of Dr.

Salzman’s mentorship of so many younger scientists.

Endowments in support of the Edmond J. Safra Family LodgeThrough endowment gifts, donors ensure perpetual

support to the Edmond J. Safra Family Lodge for its

operations and for the continued comfort of its guests.

John I. and Elaine K. Gallin EndowmentThe Gallin Endowment provides amenities for

family members of patients participating in clinical

trials at the NIH.

GlaxoSmithKline EndowmentThe GlaxoSmithKline Endowment supports

programs and activities for families of patients,

including services that help residents stay in touch

with employers and loved ones.

Harry and Jeanette Weinberg EndowmentThe Weinberg Endowment supports Edmond J.

Safra Family Lodge operations and maintenance—

ensuring that guests are provided a comfortable

home away from home for years to come.

The FNIH joins Facebook.

A grateful family anonymously gives back to the NIH Clinical Center— more than 50 years after their young daughter was successfully treated there—making generous gifts through the FNIH in support of lung cancer research.

SubPopulations and InteRmediate Outcome Measures in COPD Study (SPIROMICS) launches in partnership with NHLBI and six private-sector partners.

OMOP completes its methods feasibility and methods performance testing and characterization experiments; methods library completed and posted online.

ADNI 2 launches and begins enrollment of participants at an earlier stage of mild cognitive impairment and introduces new imaging techniques to improve understanding of how the brain changes as Alzheimer’s disease progresses.20

10

The Biomarkers Consortium announces the launch of the I-SPY 2 TRIAL, a five-year, $25 million Phase 2 clinical trial that uses biomarkers and adaptive trial design to “personalize” the development of new breast cancer drugs and reduce the time and cost of approving them. This is the first large-scale clinical trial sponsored and managed by the Foundation.

The FNIH-managed GCGH initiative discovers new approaches in delivering traditional vaccines without the need for injection or refrigeration.

| 2 0 1 1 A N N U A L R E P O R T36

and Forward

The FNIH’s Biomarkers Consortium launches a trial to develop diabetes diagnostic tools.

Popular morning talk show Live! With Regis and Kelly hosts the 2010 High Heel-A-Thon benefiting the FNIH in support of The Heart Truth®.

For the sixth consecutive year, renowned composer and conductor Marvin Hamlisch performs a holiday concert at the Edmond J. Safra Family Lodge. See page 30.

The FNIH receives a grant from the Bill & Melinda Gates Foundation for the Identification of High-quality HITS for Tuberculosis project for tuberculosis drug discovery. See page 14.

The FNIH launches the first U.S.-Russia Scientific Forum Planning Meeting supported by a $1.2 million gift from Eli Lilly and Company. See page 30.

The FNIH “tweets” for the first time on Twitter.

The FNIH launches first e-Newsletter.

The FNIH receives grants from the Bill & Melinda Gates Foundation for the renewal of CTC-VIMC and for development of a second-generation broadly neutralizing antibody product to prevent HIV-1 infection in humans.

The FNIH joins the NHLBI to spread The Heart Truth® message through its support of the Red Dress Collection 2011 Fashion Show. See page 28.20

11

There are many ways to partner with the FNIH and make a meaningful impact on human

health. Together, we can continue advancing scientific discovery and medical break-

throughs that will help diagnose and treat the most devastating diseases of our time.

Mail your philanthropic investment using the enclosed response envelope. Or give online

at www.fnih.org. To learn more about these opportunities, please contact Caite Gilmore at

301-594-2612 or [email protected].

• Give Where It’s Needed Most: By making a gift

to the FNIH and allowing us to strategically

apply it where the need is greatest, you help

develop emerging program areas and new

partnerships.

• Join the Discovery Society: Supporters who

give $1,000 or more annually receive special

acknowledgement, invitations to exclusive

events and programs and other unique

benefits (See page 39).

• Get your Company Involved: Join the FNIH

Corporate Patron Society and become a key

partner in advancing human health worldwide.

• Honor or Memorialize Someone Special: Pay

tribute to your NIH physician, family member or

friend on a special occasion; or, ask friends and

relatives to make donations in memory of a

special person in lieu of flowers.

• Establish an FNIH Fund or Endowment: Make a

meaningful, lasting impact in a specific disease

area that is important to you or a loved one by

making a significant investment in the FNIH.

• Give Through the Workplace: Multiply the

impact of your donation through your

employer’s Matching Gift Program; or, if you’re

a federal employee, make us your charity of

choice in the Combined Federal Campaign

(CFC#29165).

• Join the Legacy Society: Include the FNIH in

your estate plans to ensure that the work that

is important to you continues for generations

to come.

• Stay in Touch: For real-time updates follow us

on Facebook at www.facebook.com/FNIHorg,

Twitter @FNIH_Org, or our blog at

www.fnih.org/press/blogs.

What You Can Do


Financial SummaryREVENUE AND SUPPORT 2011 2010

Contributions 53,307,415 55,096,888

Grants 7,184,662 8,028,743

Administrative fee 336,864 300,796

Government appropriations 486,000 500,000

Investment earnings 83,763 173,518

In-kind contributions 2,037,266 1,564,550

Donated services 44,892 212,949

Return of contribution - (954,517)

TOTAL REVENUE AND SUPPORT 63,480,862 64,922,927

EXPENSES AND CHANGES IN NET ASSETSPROGRAM SERVICES

Fellowships and training programs 1,486,681 1,687,123

Memorials, awards and events 3,712,399 1,644,425

Capital Projects 38,516 45,399

Research Partnerships 44,259,013 48,914,764

TOTAL PROGRAM SERVICES 49,496,609 52,291,711

SUPPORTING SERVICES

Management and general 2,944,238 2,943,788

Fundraising 145,190 160,144

TOTAL SUPPORTING SERVICES 3,089,428 3,103,932

TOTAL EXPENSES 52,586,037 55,395,643

CHANGE IN NET ASSETS 10,894,825 9,527,284

NET ASSETS BEGINNING OF YEAR 73,538,119 64,010,835

NET ASSETS AT END OF YEAR 84,432,944 73,538,119

2011 reVenues 2011 eXPenses

the Foundation’s audited statements are available on request.

Grants 11%

Other Revenue 5%

Contributions 84% Research Partnerships 84%

Education and Events 10%

Management and Fundraising 6%

| 2 0 1 1 A N N U A L R E P O R T38

and Forward

Discovery Society The Foundation for the National Institutes of Health

offers individuals a powerful way to help advance

science, discovery and innovation. Membership in

the Discovery Society is one of them. Members

of this distinguished group receive special

acknowledgement, invitations to exclusive events

and programs and other unique benefits.

Explorer ($1,000+)• Tour of the NIH campus and Clinical Center for

you and one guest

• Invitations to FNIH programs and special events

• Subscription to the FNIH’s online newsletter

• Recognition of support on the FNIH website and

in the Annual Report

Investigator ($5,000+) All of the above benefits, plus:

• Special lunch and tour of the NIH campus and

Clinical Center for you and three guests

• Invitation to annual Holiday Luncheon

Pioneer ($10,000+) All of the above benefits, plus:

• Opportunity to name a garden bench at the

Edmond J. Safra Family Lodge*

• Opportunity for your child to participate in

Young Scientist Day

Trailblazer ($25,000+) All of the above benefits, plus:

• Opportunity to name a small guest suite or

gazebo at the Edmond J. Safra Family Lodge*

• Invitation to annual Board of Directors dinner

Visionary ($50,000+) All of the above benefits, plus:

• Opportunity to name a large guest suite at the


• Invitation to exclusive roundtable discussions

with Board of Directors

• Participation in high-level partnership meetings,

briefing sessions and conference calls on

current FNIH programs

Catalyst ($100,000+) All of the above benefits, plus:

• Opportunity to name a lounge or hall at the


• Lunch and behind-the-scenes tour of

the campus and Clinical Center with

senior leadership

• Special invitation to exclusive VIP event

* All naming opportunities will extend throughout the duration of the campaign for the Edmond J. Safra Family Lodge.

Giving Societies

A bench at the Edmond J. Safra Family Lodge garden offers people a peaceful place to rejuvenate and can be dedicated to a loved one.


Donors

$5,000,000+ Bill & Melinda Gates Foundation 10

Merck Sharp & Dohme Corp. 14

$2,500,000 – $4,999,999 Johnson & Johnson 11

Novartis Pharmaceuticals Corporation12

Pfizer Inc. 14

Sanofi * 10

Takeda Pharmaceuticals North America, Inc. 3

$1,000,000 – 2,499,999 Abbott Laboratories 4

Alzheimer’s Association 7

AstraZeneca LP 10

The Coca-Cola Company 4

Fondation d’entreprise La Mondiale GlaxoSmithKline 13

Eli Lilly and Company 12

The McKnight Brain Research Foundation 6

Pharmaceutical Research and Manufacturers of America (PhRMA) 7

$500,000 – $999,999 Arthritis Foundation 2

Bausch & Lomb Bayer HealthCare

Pharmaceuticals, Inc. 4

Biogen Idec Inc. Boehringer Ingelheim

Pharmaceuticals, Inc. 3

Critical Path Institute Foundation for Burkitt

Lymhoma Research 2

In memory of Xavier MartinNational Institutes of Health 16

Bob and Sally Newcomb Novo Nordisk Pharmaceuticals, Inc. Roche 5

$250,000 – $499,999 Amgen, Inc. 9

Belk, Inc.

Bioiberica Bristol-Myers Squibb Company 12

Eisai Inc. 5

GE Healthcare 3

The Bernard Osher Foundation 3

Quantum Leap Healthcare 2

Swarovski North America, Ltd. 2

$100,000 – $249,999 Alexandria Real Estate Equities, Inc. Amylin Pharmaceuticals, Inc. 2

Avon Foundation for Women Centocor, Inc. Daiichi Sankyo, Inc. 2

Dairy Research Institute The Dannon Company, Inc. 2

Gerber Foundation IBEX Pharmaceuticals, Inc. Institut De Recherches

Internationales Servier 2

Johnson & Johnson * 11

Robert Wood Johnson Foundation 8

Meso Scale Diagnostics, LLC 3

NYCOMED GmbH 2

Safeway Foundation Side-Out Foundation SoBran, Inc. Verizon 2

$50,000 – $99,999 Alzheimer’s Drug Discovery Foundation Ambassador and Mrs. Hushang Ansary

In memory of Stephen J. SolarzBiotechnology Industry Organization 4

Burroughs Wellcome Fund 7

Capital Technology Information Services, Inc. 2

Cerexa, Inc. Cubist Pharmaceuticals, Inc. DePuy Mitek, Inc. Duke University School of Medicine Forest Laboratories, Inc. Estate of Charles Harris Innate Pharma

Institute for the Study of Aging 2

Intel Corporation 2

McKesson Corporation 2

Nabriva Therapeutics Philips PhRMA Foundation 4

The Rockefeller Foundation Mrs. Lily Safra 10

Trius Therapeutics United Nations Foundation 2

The Walt Disney Company

$25,000 – $49,999 Actelion, Ltd. Amway AOL, Inc. AT&T Inc. 2

Beckman Research Institute of the City of Hope

BioClinica, Inc. 2

BioVendor Laboratorni medicina a.s.* Buffy and William Cafritz 8

Doris Duke Charitable Foundation 9

Hogan Lovells 2

Incyte Corporation Juvenile Diabetes Research Foundation

International 2

Estée Lauder Companies Inc. Medpace, Inc. 3

Dr. and Mrs. Paul M. Montrone 14

National Initiative for Children’s Healthcare Quality (NICHQ)

The Procter & Gamble Company 2

Qualcomm, Inc. 3

RottaPharm-Madaus Synarc, Inc. 4

UnitedHealthcare Services, Inc.Vodafone mHealth Solutions

$10,000 – $24,999 Bernard W. Abrams Family

Foundation, Inc. 3

In memory of Bernard W. AbramsAmerican Orthopaedic Society for

Sports Medicine (AOSSM)

AMS Foundation for the Arts, Sciences and Humanities 7

The Association for Frontotemporal Degeneration

Basilea Pharmaceutica International Ltd.

William C. and Paula L. Bradley 4

Buffy and William Cafritz Family Foundation 3

Celgene Corporation 2

Cempra Pharmaceuticals Chiesi Farmaceutici S.p.A. 2

Commerce One BPO, LLC Continua Health Alliance 2

Friends of Cancer Research 2

General Mills, Inc. 2

Genome British Columbia 2

Genzyme Corporation Jack Gramlich Foundation Hempling Foundation For

Homocystinuria Research Huntington’s Disease Society

of America Illumina, Inc. International Biomedical

Research Alliance Howard H. and Jacqueline K. Levine

In memory of Stephen J. SolarzFreda C. Lewis-Hall, M.D., FAPA Metanomics Health GmbH Myriad RBM 2

Parkinson’s Disease Foundation Steven and Jann Paul The Pew Charitable Trusts 3

Professional Landscape Management Services *

Profilo HoldingIn memory of Stephen J. Solarz

Jillian Sackler, D.B.E. 9

Dr. and Mrs. Charles A. Sanders 15

Jane M. Sayer, Ph.D. 10

Mr. Gerald R. and Dr. Ellen V. Sigal 9

Simon Property Group 2

Nina Solarz 2

In memory of Stephen J. SolarzVertex Pharmaceuticals, Inc.

The Foundation for the NIH would like to thank the many corporations, private foundations, associations and individuals who generously provided financial and in-kind support to the Foundation and its programs during 2011. Restricted gifts support many varied initiatives, including complex biomedical research programs; educational efforts such as fellowships, lectures and symposia that train scientists and help them build their careers; and specific laboratories or areas of scientific research at the NIH. Unrestricted gifts support core operations and enable the Foundation to develop emerging program areas and new partnerships.

The Foundation is very efficient in managing the private sector’s investment. Of every dollar spent by the Foundation, 94 cents are used to support programs and just six cents for administration and fundraising. In testament to the FNIH’s efficient management of your investment, we have been awarded—or five consecutive years—four stars by Charity Navigator. This top ranking recognizes that we execute our mission in a “fiscally responsible way, and outperform most other charities.” The Foundation gratefully acknowledges the following donors and partners who made gifts or pledges of $250 or more during 2011.

The Foundation for the NIH makes every attempt to list donors according to their wishes. Please call 301-402-5311 if you have any questions.

| 2 0 1 1 A N N U A L R E P O R T40

and Forward

$5,000 – $9,999Anonymous

Alliance Health Networks, Inc. American Academy of Dermatology American Academy of Physical

Medicine and Rehabilitation American College of

Rheumatology, Inc. American Diabetes Association 2

American Occupational Therapy Association

American Physical Therapy Association American Psychological Association American Society for Bone and

Mineral Research Association of Academic Physiatrists Bach Pharma, Inc. Battelle Ronald and Barbara Berke 2

In memory of Jenny BerkeBGI - Shenzhen Luther W. Brady, M.D. 5

In honor of Charles A. SandersBrent Foundation 2

Frank C. and Marcia M. Carlucci In memory of Stephen J. Solarz

Dr. and Mrs. James H. Cavanaugh 4

Center For Women’s Health Research 2

Clothes Off Our Back, Inc. 3

The Columbus Foundation Consumer Electronics Association Dionex Corporation 2

Anthony S. Fauci, M.D. and Christine Grady, Ph.D.

Food and Drug Aministration Alumni Association Inc.

Genome Canada Miles Gilburne and Nina Zolt 2

GlaxoSmithKline * 13

Global HIV Vaccine Enterprise William T. Grant Foundation Margaret Grieve

In memory of Stephen J. SolarzKay A. Hart

In memory of Stephen J. SolarzFred and Noreen Hassan 2

Hereditary Disease Foundation Jean Linton 9

Lupus Foundation of America March of Dimes Birth Defects

Foundation Stephen M. McLean MO BIO Laboratories, Inc. 2

Drs. Martin J. and Ann Murphy 6

In honor of Charles A. SandersMuscular Dystrophy Association National Osteoporosis Foundation National Pharmaceutical Council New England Biolabs 3

Donna Nichols 2

In memory of Jay NicholsOpGen, Inc.

Orthopaedic Research and Education Foundation

Osteoarthritis Research Society International, Inc. 2

Ron and Joy S. Paul 2

In honor of Fred and Nancy SommerPepsiCo, Inc. Victor Pinchuk Foundation

In memory of Stephen J. SolarzPromega Corporation Proof Centre of Excellence 2

Quintiles Transnational Corporation 2

Radiological Society of North America 3

Real Time Genomics, Inc. 2

Robert E. Roberts, Ph.D. 3

Rodale, Inc. 2

Second Genome Solomon H. and Elaine B. Snyder 11

Society of Investigative Dermatology SunTrust Banks, Inc. Ullmann Family Foundation 3

United States Pharmacopeial Convention

University of British Columbia Steve and Chris Wilsey 4

$1,000 – $2,499 Anonymous ABC Alnor Oil Company American Academy of Orthotists

& Prosthetists American Orthotic Prosthetic

Association John Bennett Alice S. Cho and James J. Bergera James J. and Janet Blanchard

In memory of Stephen J. SolarzMr. Zachary T. and Dr. Kathy

Bloomgarden 3

Board of Certification/Accreditation, International

Booz Allen Hamilton Inc. 4

Samuel and Gail Broder 11

Karen Brooks In memory of Stephen J. Solarz

Susan Buchanan Scott E. Campbell, Ph.D. 2

Mr. Charles Cerf and Dr. Cynthia E. Dunbar

Ross T. ChambersThe Coca Cola Foundation Ms. Laura Curtin 3

In memory of Richard CurtinStewart Daniels 3

Sanford M. Dawsey In memory of Dr. Arthur Schatzkin

Downey McGarth Group, Inc. In memory of Stephen J. Solarz

The Essence of Red Committee Ronald G. Evens, M.D. 5

In honor of John I. Gallin

Joseph M. Feczko, M.D. and Leighton K. Gleicher 4

James M. Felser, M.D. 2

Thomas L. and Ann B. Friedman In memory of Stephen J. Solarz

Randy K. Glantz and Binaife A. Davar In memory of Stephen J. Solarz

Gary Grossman In memory of Stephen J. Solarz

Thomas H. and Rita R. Hassall 3

Harley Anderson Haynes, M.D. 2

Steve and Sally Herman In memory of Dr. Arthur Schatzkin

Roderick M. and Carla A. Hills In memory of Stephen J. Solarz

Eric Hirschhorn In memory of Stephen J. Solarz

E.A. Holtzman Foundation In memory of Stephen J. Solarz

Joshua J. Howard In memory of Stephen J. Solarz

IQ Solutions 2

Mahnaz Ispahani In memory of Stephen Solarz

Alan G. Johnson In memory of Annetta Johnson

Linda H. Kamm In memory of Stephen J. Solarz

Nancy Kaplan 2

Bernard H. and Georgina E. Kaufman 2

Jules and Lynn Kroll Gail Leese 2

Franz Leichter In memory of Stephen J. Solarz

Jonathan D. Levine In memory of Stephen J. Solarz

Stephen K. and Suzanne Levine In memory of Stephen J. Solarz

James and Marie Malaro In memory of Lucille M. Decker

Robert and Margaret McNamara Foundation 2

National Association for the Advancement of Orthotics & Prosthetics

Stephen A. Novick In memory of Stephen J. Solarz

Matthew W. O’Neill 5

In memory of Dean O’NeillIzamar Ontiveros Mattison C. and Robyn Painter

In memory of Jay NicholsThe Pannonia Foundation

In memory of Stephen J. SolarzAmy and John Porter 12

Rivermap DNA Laboratory Robert E. Roberts, Ph.D. * 3

Stanley O. Roth In memory of Stephen J. Solarz

Lenore R. Salzman 14

In memory of Norman P. SalzmanEstate of Frances H. Saupe 4

Dr. and Mrs. Howard K. Schachman 7

Scleroderma Research Foundation Joel P. and Marcia Selden

In memory of Stephen J. SolarzSigma-Aldrich Corporation 3

William S. Singer 2

In memory of Stephen J. SolarzAlbert H. and Lillian Small 3

The Eddie and Jo Allison Smith Family Foundation In honor of Lanier Swann

Fred S. and Nancy T. Sommer In honor of Howard Fine

Dr. and Mrs. Stephen P. Spielberg 9

Mark A. Spiteri 5

Dr. and Mrs. David J. Steinberg In memory of Stephen J. Solarz

Thermo Fisher Scientific Inc. Samuel O. Thier, M.D. and Paula Thier 6

United States Bone and Joint Decade George F. Vande Woude, Ph.D. Tracy and Richard Waggoner

In memory of Jay NicholsMai Wang Howard M. and Nancye C. Weisberg 3

Lisa N. Whitten 2

In memory of Jay NicholsE. Bell Young

In memory of Thomas E. MaloneDrs. Elias A. and Nadia Zerhouni 3

$500 – $999 Anonymous James Bayless

In memory of Stephen J. SolarzThe Honorable and Mrs. William

McCormick Blair, Jr. 13

Boehringer Ingelheim Pharmaceuticals, Inc.* 3

Stuart Bondurant and Susan Ehringhaus 4

Tino and Dawn Calabia In memory of Stephen J. Solarz

Rina Caniza In memory of Stephen J. Solarz

Janet Carlson and Daniel Balliet 3

Conservation International In memory of Stephen J. Solarz

Lisa Crafford In memory of Stan Nebinski

Janet S. DeGilio 2

Eugene and Mary Dionne In memory of Stephen J. Solarz

Nicholas M. and Jacqueline E. Ferriter 2

James and Karen Gavic 2

Stanley and Eve Geller 6

In memory of Norman SalzmanKen and Yvette Guidry 5


Mary Frances Cotch and B. Fenton Hall 7

Robert Harris In memory of Dr. Arthur Schatzkin

Amy W. Hawthorne 2

In memory of Stephen J. SolarzEva C. Holtz 2

Laurel Jacobson 2

In memory of Stephen W. JacobsonRichard Jonas and Katherine

Vernot-Jonas 4

Julep Nail Parlor Mark Kaufman and Judith L. Harris

In memory of Dr. Arthur SchatzkinRon Kopicki and Ann Ashby The Honorable and

Ms. G. Oliver Koppell In memory of Stephen J. Solarz

Sam Lippman 2

Mattlin Foundation 3

National Marfan Foundation Nature Publishing Group Ruth Nolte Dr. Gilbert S. Omenn and

Mrs. Martha Darling 4

Mara Polan In honor of Fred and Nancy Sommer

Charles Radcliffe and Herve Verhoosel In memory of Stephen J. Solarz

James and Lora Rodenberg 2

Armand Rodriguez Gregory Roper Robert and Marjorie Rosenberg Douglas E. Schoen 2

In memory of Stephen J. SolarzDavid G. and Carole L. Schultz Stephen C. Syne Diane M. Szolyga Anne Thiebaut

In memory of Dr. Arthur SchatzkinThe Drs. Termoulet 3

Jon and Kristin Vaver 4

Michael and Marianne Walter Mrs. Henry P. Wheeler 11

Fred C. Williamson 2

Matthew Zimmerman 2

In memory of Brent K. Herrold

$250 – $499 AnonymousDr. and Mrs. N. Kirby Alton,

The Alton Foundation 2

Paul Bach In memory of Stephen J. Solarz

Jill H. Barr 3

In memory of John L. Barr

William G. Barsan, M.D. 2

Ann Beck 4

Joan Beck Edward Brannan Dr. and Mrs. Jacob A. Brody 3

Cambridge Isotope Laboratories, Inc. 2

Raymond W. Clement 3

Michael Conforti In memory of Stephen J. Solarz

Craig Corbitt and Nancy Stoltz 2

Susan G. Davis 3

Josephine F. de Give In memory of David de Give

Nancy Dougherty In memory of John N. Miller III

Carol and John Eddy 4

Scott Edgerton Brenda K. Edwards

In memory of Dr. Arthur SchatzkinDawn Fidaleo 2

Seth P. Forster 5

Peggy J. Gerlacher14

In memory of John D. GerlacherAaron Gibson 2

Drs. David Golan and Laura Green Erica L. Goldberg 2

In memory of Jeffrey KauffmanJonathan Greenblatt and

Linda A. Adams 2

In memory of Stephen J. SolarzMichael C. and Patricia M. Greer Sigurd Hermansen

In memory of Dr. Arthur SchatzkinJonathan Hiatt

In memory of Dr. Arthur SchatzkinRachel and Jamie Hirsch Stephanie L. James, Ph.D. Pamela Jeffcoat 3

Michelle Jezycki Lisa Johnson Harry and Marilyn Karasov 2

Angelos Kleanthous Dr. and Mrs. Ronald W.

Lamont-Havers 2

The Lannum Family In honor of Michael Assenza

The Paul Laxalt Group In memory of Stephen J. Solarz

Paul and Carole Laxalt In memory of Stephen J. Solarz

Michael Lenardo, M.D. Chris Lenker Robert and Bonnie Livingston

In memory of Stephen J. SolarzLouis Vuitton North America Roger A. and Barbara Michaels 2

Lilly Minkove 2

W. Tyler and Christy R. Mistr In honor of Chris Battle

Reverend and Mrs. Robert H. Naylor 2

Rosie Nebenhaus Ross In memory of Stephen J. Solarz

Anne Newman, M.D. In memory of Dr. Arthur Schatzkin

No Tears Learning Judith A. Nowak, M.D. Yikyung Park

In memory of Dr. Arthur SchatzkinMitchell Pines 5

Lisa Prickett In memory of Stephen J. Solarz

Ramerica International, Inc. 2

In memory of Stephen J. SolarzDavid C. and Marilyn Reed Charles and Lynda J. Robb

In memory of Stephen J. SolarzFu-Meei Y. Robbins Gary M. Roggin, M.D. Walter G. Rostykus and Catherine

Elliott-Rostykus 3

Marvin Schmeiser 2

Michelle Schumaker Marilyn M. Seastrom 2

Eugene Sofer and Judith Bartnoff 2

In memory of Stephen J. SolarzAlan Solomon, M.D. 2

Rainer F. Storb, M.D. Donald Thompson William Tolentino and Andre Bailey 3

James Tucker 4

Vehbi Koc Vakfi In memory of Stephen J. Solarz

Julie Wagshal Robert C. Watson, Jr. Thomas E. Wellems, M.D., Ph.D. 3

John H. Wilson 3

Howard and Julie Wolf-Rodda 5

Justin Wyman In memory of Vicki Triantos Shrum

Joyce A. Yarington 8

In memory of Edward RileyJoel Yesley 4

Charles W. Zimmerman 4

* indicates Gifts in Kind

[superscript] recognizes donors who have given consecutively for the stated number of years

| 2 0 1 1 A N N U A L R E P O R T42

and Forward

HONORARIUM GIFTS

You can honor a friend or family member for an important occasion with a gift to the Foundation for the NIH. It is a wonderful way to send good wishes for a birthday or anniversary, thanks to a friend or doctor, or congratulations for retirement, a job well done or graduation. Please include the name and address of the individual being honored so that acknowledgement of your kind donation can be sent. In 2011, the Foundation received gifts in honor of the following individuals.

LEGACY SOCIETY

The Legacy Society recognizes individuals who have informed us that they have named the Foundation for the NIH as a beneficiary in their will or estate plan. These legacy gifts can support a specific NIH program, area of research or other identified need, or they may provide unrestricted support to the Foundation. We thank the following individuals who have named the Foundation as a beneficiary.

AnonymousJudy BelousThe Honorable and Mrs. William McCormick Blair, Jr.Paula L. BradleyPatricia S. KohlenDrs. Zell and Emily KravinskyPatricia NowosackiRobert E. Roberts, Ph.D.Jane M. Sayer, Ph.D.Dr. and Mrs. Robert F. WagnerSusan M. Wall, M.D.

MEMORIAL GIFTS

Contributions are given to the Foundation for the NIH at the request of family members in memory of loved ones. These generous contributions enhance our ability to support the NIH in its mission to improve health, by forming and facilitating public-private partnerships for biomedical research, education and training. We extend our sympathies to the family and friends of those memorialized below.

Bernard W. AbramsArlene AlexanderJack ArnesenJohn L. BarrJenny BerkeIgor BirmanDoris BlumeKris BlumeJames S. BrockmanDenis J. BuksaRobert BurnsBennett CamhiMarcella Cheslow HolzmanJohn CookendorferBrian CrehanRichard CurtinAnnie L. DavisDavid de GiveJohn L. DeckerLucille M. DeckerDavid DerseSylvia DiamondSherita DurbinJohn D. FoutPaul A. GattiniJohn D. GerlacherBrent K. HerroldNicholas P. HumyStephen W. JacobsonAnnetta JohnsonMark A. KapouralosJeffrey E. Kauffman

Marilyn KotwalPanagiota KoutroubinisMichael KuchinskyErin M. KurtzCatherine MalavendraThomas E. MaloneMichael C. MarrXavier MartinEyal MichelsonMichael T. MiddletonCarlton MillerJohn N. MillerStan C. NebinskiArthur NepiarskyJay NicholsDean R. O’NeillMelissa PalmerRichard C. PottsJennifer R. PriceLindsey RenschEdward RileyMorton RolnickMyrna L. RubensteinNorman P. SalzmanArthur G. SchatzkinAbe SchwartzAmy SiegelStephen J. SolarzVicki Triantos ShrumTheresa ValentiFrancis E. WeberRobert A. Welch

Annette B. AbramsMichael AssenzaChris BattleConnie BeckerHoward A. FineBetty J. GaffneyJohn I. GallinKurt GerstmannFred A. GillCarter Mae HayesDianne HepkeStephen I. KatzRajeev MalikMatt Maples

Tom MayRead MeclearyTurner PierceAlan RosenbergAlison B. RubensteinCharles A. SandersAlfred SommerFred S. SommerNancy T. SommerLanier SwannKristen R. ThompsonCamilo ToroThomas Tuten

$21 $29 $27 $125 $158 $164 $177 $148 $135 $134

FUNDRAISING | Money raised for every dollar of government appropriation received

$1

$1

$1 $1

$1

$1

$1

2002 2003 2004 2005 2006 2007 2008 2009 2010 2011


2011 Board of Directors

Charles A. Sanders, M.D.Retired Chairman and CEOGlaxo, Inc.

The Honorable John Edward PorterHogan Lovells

Officers

Chairman Vice Chairman

Paul M. Montrone, Ph.D.Chairman, Perspecta TrustExecutive Chairman & Founding Partner, Liberty Lane Partners

Treasurer

Mrs. William McCormick Blair, Jr.Director Emeritus Albert and Mary Lasker Foundation

Secretary

Kathy Bloomgarden, Ph.D.Chief Executive Officer, Ruder Finn Inc.

Mrs. William (Buffy) N. CafritzTrustee, The John F. Kennedy Center for the Performing Arts

Joseph M. Feczko, M.D.Retired Senior Vice President and Chief Medical Officer, Pfizer Inc

Miles GilburneManaging Member, ZG Ventures, LLC

Freda C. Lewis-Hall, M.D., FAPAChief Medical Officer, Senior Vice President, Pfizer Inc

Caroline Kovac, Ph.D.Retired General Manager, IBM Healthcare and Life Sciences

Sherry LansingFounder and Chair, The Sherry Lansing Foundation

Ann LuriePresident, Lurie Investments, Inc.President and Treasurer, Ann and Robert H. Lurie FoundationPresident, Africa Infectious Disease Village Clinics, Inc.

Martin J. Murphy Jr., Ph.D.Founding Chairman and Chief Executive Officer,AlphaMed Consulting, Inc.

Steven M. Paul, M.D.Assistant Professor of Neuroscience,Weill Cornell Medical College

Philip A. Pizzo, M.D.Dean, Stanford University School of Medicine

Jillian Sackler, D.B.E.President and CEO, AMS Foundation for the Arts,Sciences & Humanities

Mrs. Lily SafraChairman, The Edmond J. Safra PhilanthropicFoundation

Kurt L. SchmokeDean, Howard University School of Law

Ellen V. Sigal, Ph.D.Chairperson, Friends of Cancer Research

Solomon H. Snyder, M.D.Director, Department of NeuroscienceJohns Hopkins University School of Medicine

Stephen P. Spielberg, M.D., Ph.D.Marion Merrell Dow Endowed Chair in Pediatric PharmacogenomicsDirector, Center for Personalized Medicine and Therapeutic InnovationProfessor of Pediatrics and PharmacologyChildren’s Mercy Hospital and Clinics, Kansas City

Samuel O. Thier, M.D.Professor of Medicine and Health Care Policy, EmeritisHarvard Medical School, Massachusetts General Hospital

Anne WojcickiCo-Founder, 23andMe

Director Emeritus

Paul Berg, Ph.D.Cahill Professor in Biochemistry (Emeritus), StanfordUniversity School of Medicine

Honorary Directors

Luther W. Brady, M.D.Hylda Cohn/American Cancer Society,Professor of Clinical Oncology andProfessor, Department of Radiation OncologyDrexel University College of Medicine

Patrick C. Walsh, M.D.University Distinguished Service Professor, JamesBuchanan Brady Urological InstituteJohns Hopkins Medical Institutions

Ex Officio Non-Voting Directors

Francis S. Collins, M.D., Ph.D.Director, National Institutes of Health

Margaret Hamburg, M.D.Commissioner, Food and Drug Administration

| 2 0 1 1 A N N U A L R E P O R T44

and Forward

2011 Foundation for the NIH Staff Executive Director’s Office

Scott E. Campbell, Ph.D. Executive Director and CEO

Ann Ashby, M.B.A. Deputy Executive Director

Jenna Mills Palfrey Communications Manager

Tara L. JacobOperations Administrator and Senior Executive Assistant

Joshua A. Walker Senior Executive Assistant

Elizabeth S. Johns Operations Assistant

Kai Yee Web Administrator

Michelle Jezycki, MAOMDirector, Human Relations

Finance

Julie Tune, CPA, CFE Chief Financial Officer

Eva Coyne, CPA Accounting Manager

Noemi B. Rodriguez Staff Accountant

Peggy J. Gerlacher Operations Associate

Michelle McGillStaff Accountant

Marketing And Strategic Alliances

Richard M. ScarfoDirector

Peggy M. Diab Manager, Events and Marketing

Bonnie Knight Manager, Corporate Relations and Sponsorships

Chianti C. SeitzEvents Coordinator

Laura HarwoodEvents Coordinator

Michael Waterman Executive Assistant

Development

Julie Wolf-Rodda, M.A. Director, Partnership Development

Andrea Baruchin, Ph.D. Director, NIH Relations

Erika Tarver NIH Projects Officer

Alison Drone, M.A. Partnership Development Officer

Donna Batcho, M.P.A.Partnership Development Officer, Individual and Planned Giving

Caitlin Gilmore Partnership Development Officer, Major Gifts

Paris L. A. Moore Partnership Development Officer, Biomarkers Consortium

William Tolentino Development Systems Administrator

Kathy GuireExecutive Assistant

Science Administration

Stephanie James, Ph.D.Director of Science and Director, Grand Challenges in Global Health

Michael Gottlieb, Ph.D. Deputy Director of Science

Dennis Lang, Ph.D. Senior Program Coordinator, MAL-ED

Rebecca Blank, Ph.D.Scientific Program Manager, MAL-ED

Susan Powell, M.T.S. Grants Manager

Magda Galindo Assistant Grants Manager

Susan Wiener, M.A. Project Manager, Grand Challenges in Global Health

Gail Levine, M.A., CRCCScientific Program Manager,CTC-VIMC

Anna Sambor, M.S. Project Manager, CTC-VIMC

Jan FowlerExecutive Assistant

Observational Medical Outcomes

Partnership (OMOP)

Tom Scarnecchia, M.S. Executive Director

Emily Welebob, R.N., M.S. Senior Program Manager, Research

Christian Reich, M.D., Ph.D. Senior Program Manager, IT

Biomarkers Consortium

David Wholley, M.A.Director

David Lee, M.P.A.Deputy Director

Maria Vassileva, Ph.D. Scientific Program Manager, Metabolic Disorders

Sonia Pearson-White, Ph.D. Scientific Program Manager, Cancer

Judy Siuciak, Ph.D. Scientific Program Manager, Neuroscience

Karen H. Tountas, Ph.D. Scientific Program Manager, Inflammation & Immunity

Jessica Ratay, M.S., CGC Clinical Project Manager

Cheryl Melencio Executive Assistant

DE

SIG

N: D

on S

chaa

f &

Frie

nds,

Inc.

| w

ww

.dsf

riend

s.co

m


Partners for Innovation, Discovery, Health

9650 Rockville Pike Bethesda, MD 20814-3999 USA

301-402-5311

www.fnih.org

All rights reserved. This material may be quoted or reproduced without charge for noncommercial purposes only; however, please acknowledge the source.

The full text of this report is also available online at www.fnih.org

2011 FNIH Annual Report

Documents

Transcript of 2011 FNIH Annual Report